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Report on the risk assessment of 
1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one 
(α-pyrrolidinovalerophenone, α-PVP) in the 
framework of the Council Decision on new 
psychoactive substances
About this series
EMCDDA Risk Assessments are publications 
examining the health and social risks of 
individual new psychoactive substances.
The Risk Assessment Report consists of an 
analysis of the scientific and law enforcement 
information available on the new psychoactive 
substance under scrutiny and the implications 
of placing it under control. It is the outcome 
of a meeting convened under the auspices of 
the EMCDDA Scientific Committee.
This process is part of a three-step procedure 
involving information exchange/early warning, 
risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I Foreword
This publication presents the data and findings of the risk assessment on α-PVP (1-phenyl-
2-(1-pyrrolidinyl)-1-pentanone), carried out by the extended Scientific Committee of the 
EMCDDA on 18 November 2015.
The Risk Assessment Report, which was submitted to the European Commission and the 
Council of the European Union on 26 November 2015, examines the health and social risks 
of the drug, information on international trafficking and the involvement of organised crime, 
as well as a consideration of the potential implications of subjecting the drug to control 
measures. α-PVP is the eleventh new psychoactive substance to be risk assessed under 
the terms of Council Decision 2005/387/JHA.
On the basis of the Risk Assessment Report — and on the initiative of the European 
Commission — on 27 June 2016, the Council decided that α-PVP should be subject to 
control measures across the Member States. This decision was adopted in the final stage 
of the three-step process — early warning, risk assessment and control of new 
psychoactive substances — established by the Council Decision 2005/387/JHA. This 
legal framework allows the EU institutions and Member States to act on all new and 
potentially threatening narcotic and psychotropic drugs which appear on the European 
drug scene, with the EMCDDA and Europol, in collaboration with their respective networks 
playing a central role in the early detection of such substances as well as the harms 
caused by their use — information that underpins risk assessment, and, ultimately, 
decision making.
In this respect we would like to acknowledge the excellent work done by the networks of 
the EMCDDA and Europol, as well as those of the EMA — the Reitox national focal points, 
Europol national units and the national competent authorities responsible for medicinal 
products — who played an essential role in collecting and providing national data.
Finally, we would like to thank all the participants in the risk assessment process for the 
high quality of work carried out. The resulting report is a valuable contribution at European 
level, which gives clear support to political decision-making.
Professor Dr Gerhard Bühringer
Chair, Scientific Committee of the EMCDDA
Alexis Goosdeel
Director, EMCDDA
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I EMCDDA actions on monitoring and responding to new drugs
The EMCDDA has been assigned a key role in the detection and assessment of new drugs 
in the European Union under the terms of a Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances. It 
establishes a mechanism for the rapid exchange of information on new psychoactive 
substances and provides for an assessment of the risks associated with them in order to 
permit the measures applicable in the Member States for the control of narcotic and 
psychotropic substances to be applied also to new psychoactive substances.
The three-step process involves information exchange/early warning, risk assessment and 
decision-making (see below). More detailed information can be found in the section ‘Action 
on new drugs’ of the EMCDDA’s website: 
www.emcdda.europa.eu/activities/action-on-new-drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange,
risk-assessment and control of new psychoactive substances:
I. Information exchange
Early-warning system (EWS) EMCDDA–Europol Joint Reports
III. Decision-making Council Decisions on control
II. Risk assessment EMCDDA Risk Assessments
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Europol–EMCDDA Joint Report on 1-phenyl-
2-(1-pyrrolidinyl)-1-pentanone (α-PVP) — a summary
Europol–EMCDDA Joint Report on a new psychoactive substance: 1-phenyl-
2-(1-pyrrolidinyl)-1-pentanone (α-PVP) — in accordance with Article 5 of Council 
Decision 2005/387/JHA on the information exchange, risk assessment and control 
of new psychoactive substances
At the end of May 2015, the EMCDDA and Europol examined the available information on 
a new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known 
by the abbreviation ‘α-PVP’, through a joint assessment based upon the following criteria: 
(1) the amount of the material seized; (2) evidence of organised crime involvement; 
(3) evidence of international trafficking; (4) analogy with better-studied compounds; 
(5) evidence of the potential for further (rapid) spread; and (6) evidence of cases of serious 
intoxication or fatalities.
The EMCDDA and Europol agreed that the information available on α-PVP satisfied all 
criteria (1 to 6). The two organisations therefore concluded that sufficient information has 
been accumulated to merit the production of a Joint Report on α-PVP as stipulated by 
Article 5.1 of the Decision. Accordingly, the NFPs, the Europol national units (ENUs), the 
EMA and the World Health Organization (WHO) were formally asked to provide the relevant 
information within six weeks from the date of the request, i.e. by 8 July 2015.
The resulting Joint Report on α-PVP was submitted to the Council, the Commission and 
the EMA on 3 August 2015. The report concluded that the health and social risks, caused 
by the use of, the manufacture of, and traffic in α-PVP, as well as the involvement of 
organised crime and possible consequences of control measures, could be thoroughly 
assessed through a risk assessment procedure as foreseen by Article 6 of Council 
Decision 2005/387/JHA.
The full text of the Joint Report can be found at: 
www.emcdda.europa.eu/publications/joint-reports/alpha-pvp
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Risk Assessment Report on a new 
psychoactive substance: 1-phenyl-2-
(pyrrolidin-1-yl)pentan-1-one 
(α-pyrrolidinovalerophenone, α-PVP)
I Introduction
This Risk Assessment Report presents the summary 
findings and the conclusion of the risk assessment 
carried out by the extended Scientific Committee of the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) on the new psychoactive 
substance 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one, 
commonly known as α-pyrrolidinovalerophenone 
(α-PVP). The report is intended for policymakers and 
decision-makers in the institutions of the European 
Union.
The report has been prepared and drafted in accordance 
with the conceptual framework and the procedure set 
out in the risk assessment operating guidelines (1). It is 
written as a stand-alone document, which presents 
a summary of the information considered during the 
detailed analysis of the scientific and law enforcement 
data available at this time. The conclusion section of the 
report summarises the main issues addressed and 
reflects the opinions held by the members of the 
Scientific Committee. A list of the information resources 
considered by the Scientific Committee, including 
a detailed technical report on α-PVP, is provided below. 
This Risk Assessment Report should be read and 
understood in conjunction with the Technical report on 
α-PVP (Annex 1).
The risk assessment has been undertaken in compliance 
with Article 6 of Council Decision 2005/387/JHA of 10 
May 2005 on the information exchange, risk assessment 
and control of new psychoactive substances (2) 
(hereafter ‘Council Decision’). The Council Decision 
establishes a mechanism for the rapid exchange of 
information on new psychoactive substances (hereafter 
(1) EMCDDA (2010), Risk assessment of new psychoactive substances: 
operating guidelines, Publications Office of the European Union, 
Luxembourg. Available at: www.emcdda.europa.eu/html.cfm/
index100978EN.html
(2) OJ L 127, 20.5.2005, p. 32.
‘EU Early Warning System’ (3)) that may pose public 
health and social threats, including those related to the 
involvement of organised crime. Thus, it allows the 
institutions of the European Union and the Member 
States to act on all new narcotic and psychotropic 
substances (4) that appear on the European Union drug 
market. The Council Decision also provides for an 
assessment of the risks associated with these new 
psychoactive substances so that, if necessary, control 
measures can be applied in the Member States for 
narcotic and psychotropic substances (5).
α-PVP was formally notified to the EMCDDA through the 
EU Early Warning System in April 2011 by France, in 
accordance with Article 4 of the Council Decision. The 
notification related to the seizure of approximately 5 kg 
of a white powder containing α-PVP and pentedrone 
which was seized by French customs authorities in 
February 2011. Following an assessment of the available 
information on α-PVP, and in accordance with Article 5 
of the Council Decision, on 3 August 2015 the EMCDDA 
and Europol submitted to the Council of the European 
Union, the European Commission, and the European 
(3) The information exchange mechanism laid down by the Council 
Decision is operationalised as the European Union Early Warning 
System on New Psychoactive Substances (‘EU Early Warning System’). 
It is operated by the EMCDDA and Europol in partnership with the 
Reitox national focal points and Europol National Units in the Member 
States, the European Commission, and the European Medicines 
Agency.
(4) According to the definition provided by the Council Decision, a ‘new 
psychoactive substance’ means a new narcotic drug or a new 
psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ 
means a substance in pure form or in a preparation that has not been 
scheduled under the 1961 United Nations Single Convention on 
Narcotic Drugs, and that may pose a threat to public health 
comparable to the substances listed in Schedules I, II or IV; ‘new 
psychotropic drug’ means a substance in pure form or in a preparation 
that has not been scheduled under the 1971 United Nations 
Convention on Psychotropic Substances, and that may pose a threat 
to public health comparable to the substances listed in Schedules I, II, 
III or IV.
(5) In compliance with the provisions of the United Nations Single 
Convention on Narcotic Drugs of 1961 and the United Nations 
Convention on Psychotropic Substances of 1971.
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Medicines Agency (EMA), a Joint Report on α-PVP (6). 
Taking into account the conclusion of the Joint Report, 
and in accordance with Article 6 of the Council Decision 
on 15 September 2015, the Council formally requested 
that ‘the risk assessment should be carried out by the 
extended Scientific Committee of the EMCDDA and be 
submitted to the Commission and the Council within 
twelve weeks from the date of this notification’.
In accordance with Article 6.2, the meeting to assess the 
risks of α-PVP was convened under the auspices of the 
Scientific Committee of the EMCDDA with the 
participation of four additional experts designated by the 
Director of the EMCDDA, acting on the advice of the 
Chairperson of the Scientific Committee, chosen from 
a panel proposed by Member States and approved by 
the Management Board of the EMCDDA. The additional 
experts were from scientific fields that were either not 
represented, or not sufficiently represented on the 
Scientific Committee, and whose contribution was 
necessary for a balanced and adequate assessment of 
the possible risks of α-PVP, including health and social 
risks. Furthermore, two experts from the Commission, 
one expert from Europol, and one expert from the 
European Medicines Agency (EMA) participated in the 
risk assessment. The meeting took place on 18 
November 2015 at the EMCDDA in Lisbon. The risk 
assessment was carried out on the basis of information 
provided to the Scientific Committee by the Member 
States, the EMCDDA, Europol and the EMA. A list of the 
extended Scientific Committee, as well as the list of 
other participants attending the risk assessment 
meeting, is annexed to this report (Annex 2).
For the risk assessment, the extended Scientific 
Committee considered the following information 
resources:
i. Technical report on 1-phenyl-2-(pyrrolidin-1-yl)
pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) 
(Annex 1);
ii. EMCDDA–Europol Joint Report on a new 
psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-
1-pentanone (α-PVP) (6);
(6) EMCDDA and Europol (2015), EMCDDA–Europol Joint Report on 
a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-1-
pentanone (α-PVP), EMCDDA, Lisbon. Available at: www.emcdda.
europa.eu/publications/joint-reports/alpha-pvp 
iii. Scientific articles, official reports, grey literature, 
Internet drug discussion forums and related websites 
(hereafter ‘user websites’);
iv. Data from EMCDDA monitoring of Internet vendors 
offering α-PVP (which typically appear to be 
manufacturers and/or wholesalers and/or retailers);
v. The EMCDDA operating guidelines for the risk 
assessment of new psychoactive substances (1); and,
vi. Council Decision 2005/387/JHA of 10 May 2005 on 
the information exchange, risk assessment and 
control of new psychoactive substances (2).
Finally, it is important to note that this risk assessment 
report contains a discussion of the available information 
on serious adverse events such as acute intoxications 
(typically presenting to hospital emergency 
departments) and deaths associated with α-PVP. Such 
information is critical to the identification of emerging 
toxicological problems associated with new 
psychoactive substances within the European Union. In 
this context, it is important to recognise that the 
capacity to detect, identify, and report these events 
differs both within and between Member States. In the 
past few years, programmes have been introduced in 
some Member States to strengthen these capacities. In 
addition, the EMCDDA’s toxicovigilance system, which 
forms a central component of the EU Early Warning 
System, has also been strengthened. As a result, more 
information is available; however, it is likely that serious 
adverse events such as these remain under-detected.
I  Physical, chemical and pharmacological description 
α-PVP is a pyrrolidine cathinone (7) derivative, where the 
nitrogen is part of a pyrrolidine ring and a propyl chain is 
attached to the alpha carbon. α-PVP shares these 
structural features with pyrovalerone and 
methylenedioxypyrovalerone (MDPV), both of which are 
psychostimulants controlled under the United Nations 
Convention on Psychotropic Substances of 1971 
(Figure 1).
(7) Cathinone is a naturally occurring psychostimulant which is one of the 
psychoactive principles of the khat plant (Catha edulis Forsk). 
Cathinone is controlled under the United Nations Convention on 
Psychotropic Substances of 1971.
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FIGURE 1
The molecular structure, IUPAC name, common name, 
molecular formula, molecular weight, and monoisotopic 
mass, of α-PVP. The structures of pyrovalerone and 
MDPV are provided for comparison. Chiral centres are 
denoted by an asterisk on the molecular structures.
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The hydrochloride salt of α-PVP is described as a white, 
crystalline powder. Information provided from seizures 
and collected samples reported by the Member States 
have usually noted the presence of α-PVP in powder and 
tablet form.
α-PVP contains a stereogenic centre thus allowing for 
the existence of a pair of enantiomers: (S)-α-PVP and 
(R)-α-PVP. There is no information on the isomeric 
composition of the samples of α-PVP detected within 
the European Union; in part this may reflect the fact that 
stereochemical analysis is not routinely undertaken in 
forensic laboratories.
Analysis of α-PVP is straightforward with suitable 
equipment such as gas chromatography–mass 
spectrometry (GC-MS), liquid chromatography–mass 
spectrometry (LC-MS), Fourier transform infrared 
spectroscopy (FTIR) and nuclear magnetic resonance 
(NMR). Detection in biological matrices however may 
require the implementation of a more complex sample 
preparation procedure. The availability of analytical 
reference material is important for correct identification 
and for facilitating the quantification of α-PVP in physical 
samples and in biological matrices. Such reference 
materials are commercially available.
| Route of administration and dosage
Typical routes of administration for α-PVP include nasal 
insufflation, injection (intravenous) and oral. Other routes 
have also been reported. Limited information from user 
websites suggests that a range of doses may be used and 
that these may depend on the route of administration. 
Self-reported user experiences have noted that in some 
individuals the ‘threshold’ level for α-PVP (that is the dose 
required to induce an effect which the user can perceive) 
may occur with oral doses of 1–2 mg; ‘strong’ effects were 
reported with oral doses of 20–25 mg.
| Pharmacodynamics
The available evidence indicates that α-PVP is a potent 
psychostimulant.
In vitro studies suggest that α-PVP acts predominantly 
as an inhibitor of dopamine (DA) uptake at the dopamine 
transporter (DAT) and norepinephrine (NE) uptake at the 
norepinephrine transporter (NET). This is a phenomenon 
that is also known to occur with other psychostimulants 
with monoamine uptake properties, such as MDPV. 
Importantly α-PVP does not inhibit serotonin (5-HT) 
uptake at the serotonin transporter (SERT), which is 
a similar finding to MDPV. Information about the 
pharmacology of the individual enantiomers of α-PVP 
has not been published. Information on the effect of 
α-PVP on other pharmacological targets is not available.
Information from animal studies suggests that the effects 
of α-PVP are similar to those observed with other 
psychostimulants such as MDPV, cocaine and 
methamphetamine, where the roles of catecholaminergic 
mechanisms are well established. The neurochemical 
and behavioural features associated with α-PVP include 
locomotor activation, detection of increased levels of 
extracellular dopamine levels in mice striatum using 
microdialysis, and full substitution for the discriminative 
stimulus effects of cocaine and methamphetamine. 
Similar to MDPV, α-PVP was shown to act as a reinforcer 
when studied by conditioned place preference and using 
intravenous self-administration in rats.
| Pharmacokinetics
Studies on the pharmacokinetics of α-PVP are limited to 
determination of metabolites. These studies have 
identified a number of metabolites including HO-α-PVP 
diastereomers, 2’’-oxo-α-PVP, 2’’-HO-α-PVP, and 
HO-α-PVP glucuronide. The pharmacology and 
toxicology of these metabolites is unknown.
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There are no published data on the interaction of α-PVP 
with other substances, including other psychoactive 
substances and medicinal products.
| Psychological and behavioural effects
Information from animal studies suggests that the acute 
behavioural effects of α-PVP might bear some 
similarities to other psychostimulants such as MDPV, 
cocaine and methamphetamine.
There are no published data on the psychological and 
behavioural effects of α-PVP in humans. Limited 
information from acute intoxications and self-reported 
user experiences suggests that the effects of α-PVP 
might be broadly similar to other psychostimulant drugs 
such as MDPV.
| Legitimate uses
α-PVP and its enantiomers are used in scientific 
research as well as analytical reference materials in 
clinical and forensic case work. There are currently no 
other indications that α-PVP may be used for other 
legitimate purposes. There are no reported uses of 
α-PVP as a component in industrial, cosmetic or 
agricultural products.
α-PVP does not appear to have an established or 
acknowledged medical value or use (human or veterinary) 
in the European Union. There is no marketing 
authorisation (existing, ongoing or suspended) for α-PVP 
in the European Union or in the Member States that 
responded to the information request by the EMA that 
was launched under Article 5 of the Council Decision (6). 
In addition, there is no information that α-PVP is used for 
the manufacture of a medicinal product or an active 
pharmaceutical ingredient of a medicinal product in the 
European Union (6). It is important to note that the data 
collection is incomplete and some countries indicated 
that this information is unknown. It should also be noted 
that there is no European Union database on the synthetic 
routes of all registered medicinal products. Therefore, the 
use of α-PVP cannot be ruled out with certainty.
I  Chemical precursors that are used for the manufacture 
Currently there is no information regarding the chemical 
precursors, or the synthetic routes used for the α-PVP 
that has been detected on the drug market within the 
European Union.
Methods for the production of α-PVP are documented in 
the scientific literature. The production of α-PVP is 
relatively straightforward, in that it does not require 
a high level of technical expertise, training or 
complicated laboratory equipment. Typically, synthesis 
of cathinone derivatives can be completed at room 
temperature, requiring access to the appropriate starting 
materials and standard laboratory equipment. Methods 
documented include α-halogenation of 1-phenylpentan-
1-one (valerophenone) followed by amination with 
pyrrolidine. Of note here is that the synthesis of 
cathinone derivatives in general can be completed using 
this particular route. Valerophenone is commercially 
available; it is not controlled under the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988. Valerophenone may 
also be obtained from a variety of other starting 
materials such as benzaldehyde. Benzaldehyde is 
commercially available; it is not listed under the 1988 
Convention but is listed in the European Union voluntary 
monitoring list of non-scheduled substances. Other 
routes have also been reported and include the use of 
Grignard conditions, reaction of an epoxide intermediate 
with pyrrolidine, or involvement of the ephedrine-type 
precursor.
Detailed information regarding the presence of side-
products or impurities arising from the synthetic process 
is not available. There is no quantitative data on 
impurities detected in drug samples from the European 
market. Nonetheless, the presence of route-specific 
impurities in samples of α-PVP is possible.
I Health risks
| Individual health risks
The assessment of individual health risks includes 
consideration of the acute and chronic toxicity of α-PVP, 
as well as its abuse liability and dependence potential. 
Similarities to, and, differences from, other chemically or 
pharmacologically related substances should also be 
considered.
It is important to note that when interpreting information 
on acute intoxications and deaths as well as information 
from user websites, individuals may have used other 
pharmacologically active substances in addition to 
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α-PVP. The presence of and/or interaction with other 
substances may account for the effects reported.
The mode of use of α-PVP may involve the combined use 
of other drugs (either intentionally or unintentionally). 
This may be especially the case when α-PVP is 
encountered within powders offered and disguised in 
combination with other substances and ecstasy-type 
tablets. Analyses of various seized products have shown 
that the composition can differ and the user is unlikely to 
be aware of the exact dose or substance(s) being 
ingested (by whatever route) which presents an inherent 
risk to the individual.
| Acute toxicity
The median lethal dose (LD
50
) of α-PVP hydrochloride 
administered intravenously to mice is 38.5 mg/kg. No 
other studies were identified that investigated the acute 
health effects of α-PVP and/or its metabolites in 
animals.
No clinical studies were identified that have examined 
the acute health effects of α-PVP and/or its metabolites 
in humans.
Acute intoxications
205 acute intoxications associated with α-PVP were 
reported by eight Member States. These occurred 
between 2011 and 2015. Typically these cases related to 
acute presentations at hospital emergency departments. 
In 191 of these cases α-PVP was analytically confirmed 
in one or more biological sample taken from the patient. 
Case level data was available for 29 of these cases; 23 
were non-fatal intoxications and in the remaining 6 
cases the outcome was unknown.
Of these 29 cases, 24 were male and 4 were female; 
data on sex was missing for one case. The mean age of 
the male cases was 33.9 years (n = 21; median 32 years); 
data on age was missing for four male cases. The mean 
age of the female cases was 24.3 years (n = 4; median 
24.5 years).
In about 50 % of the cases other drugs, particularly 
benzodiazepines, were identified. Clinical features were 
generally consistent with sympathomimetic toxicity. 
These included: tachycardia, mydriasis, agitation or 
anxiety, tremor, hyperthermia, hallucinations, 
hypertension, diaphoresis, restlessness, convulsions or 
seizures. Of those cases where the route of 
administration was known, nasal insufflation, injection 
and oral routes were reported.
Deaths
A total of 116 deaths associated with α-PVP were 
reported by eight Member States. These occurred 
between 2012 and 2015. In 115 of these cases, α-PVP 
was analytically confirmed in one or more biological 
sample taken from the decedents. Of these:
 § In 23 (20 %) cases, α-PVP was reported as the cause 
of death or was reported as a contributing factor (i.e. 
α-PVP was explicitly mentioned). This includes 5 (4 %) 
cases where α-PVP was the only substance detected.
 § In the remaining cases the cause of death was 
unknown or an alternative cause of death was 
reported. In the latter case, the manner of death 
varied and included: hanging, drowning, fall, road 
traffic accident, carbon monoxide, blood loss, as well 
as cited drug intoxication.
In a majority of deaths, a wide variety of other 
substances were also detected. This included 
benzodiazepines, alcohol, opiates, opioids, 
antidepressants and anticonvulsants. Of the other 
stimulants detected these included amphetamines, 
pseudoephedrine and synthetic cathinones (e.g. MDPV, 
pentedrone, 4-MEC, 3-MMC). Synthetic cannabinoids 
were also detected in some cases.
In all of the deaths there was a lack of information 
regarding the amount of α-PVP used, the route of 
administration and any clinical features experienced 
prior to death. However, in those instances where clinical 
features have been described, tachycardia, 
hyperthermia, diaphoresis, agitation, convulsions or 
seizures, confusion, aggression, bizarre behaviour and 
rhabdomyolysis were reported. Although other drugs 
were detected with most of these cases — including 
stimulants — the symptoms are generally consistent 
with those seen in acute intoxications.
Ability to operate machinery and drive
Any adverse behavioural effects of α-PVP may also 
extend to the ability to operate machinery and drive 
safely. Aggregated data related to cases of suspected 
driving under the influence of drugs (DUID) were 
reported to the EMCDDA. There are insufficient data 
available to discuss the circumstances of these cases. 
However, data suggests that stimulants can have 
detrimental effects on self-perception, critical judgement 
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and risk-taking, and while the stimulating effects are 
wearing off the driver may suffer fatigue, anxiety and 
irritability.
| Chronic toxicity
No studies were identified that investigated the chronic 
health effects of α-PVP and/or its metabolites in 
animals. No clinical studies were identified that have 
examined the chronic health effects of α-PVP and/or its 
metabolites in humans.
| Abuse liability and dependence potential
No studies were identified that have investigated the 
abuse liability and dependence potential of α-PVP in 
humans. Data from in vitro and animal studies strongly 
suggest that α-PVP has abuse liability and possibly 
a dependence potential in humans.
| Public health risks
The public health risks associated with α-PVP may be 
categorised in terms of patterns of use (extent, 
frequency, route of administration, etc.); availability and 
quality of the drug; information, availability and levels of 
knowledge amongst users; and negative health 
consequences. Detailed information, including data on 
sporadic versus chronic use, that allow for 
a determination of public health risks associated with 
α-PVP are unavailable.
Extent, frequency, and patterns of use
There appear to be no data from general population 
surveys on the prevalence of α-PVP use. Data on the use 
of α-PVP within the European Union are limited to 
non-representative studies.
The available data suggests that α-PVP is used by 
recreational users and problem drug users. In the latter 
case this includes people who inject opioid and 
stimulant drugs, some of whom are attending low-
threshold harm reduction services and drug treatment 
services, including opioid substitution treatment 
services. The available data also suggests that polydrug 
use might be common in those using α-PVP.
Availability and quality on the market
α-PVP has been detected in all 28 Member States.
Data from seizures reported to the EMCDDA suggest 
that, in general, bulk quantities of α-PVP in powder form 
are mainly imported into the European Union from China. 
In addition to importation, two illicit production sites 
synthesising α-PVP have been seized in Poland; the 
α-PVP was intended for the domestic market and export. 
More than 750 kg of α-PVP in powder form has been 
seized in Europe since 2011. In most cases α-PVP has 
been seized as a powder, but other forms including 
tablets have been detected.
α-PVP is offered for sale in small retail quantities 
(1 g upwards) and in wholesale (kilogram) quantities by 
Internet retailers as a drug in its own right. The purity of 
these products may be claimed to be high but this has 
not been reported.
Detailed information available with regards to route-
specific by-products produced during the synthesis of 
α-PVP is currently not available. There are no 
quantitative data available on the impurities detected in 
seized and collected samples reported to the EMCDDA 
by the Member States. Information on purity was only 
available for 17 seizures reported to the EMCDDA. Here 
the content of α-PVP ranged from 23 % (2 seizures) to 
over 95 % (8 seizures). In most cases, α-PVP was 
reported as the only active substance, although in about 
35 % of detections it was found in combination with 
other substances (predominantly stimulants). In these 
cases, quantitative analyses were not available.
Characteristics and behaviour of users
The available data suggests that α-PVP is used by 
recreational drug users and problem drug users. In the 
latter case, this includes people who inject opioid and 
stimulant drugs. Some of this group include individuals 
who are attending low-threshold harm reduction 
services and drug treatment services, including opioid 
substitution treatment services. The data also suggests 
that polydrug use might be common in those using 
α-PVP. Further information on the size and demand and 
the characteristics of these groups of people is not 
available.
As noted, the available data suggests that α-PVP is used 
by problem drug users including those who inject 
stimulants and opioids. Drug injection is associated with 
health risks which include transmission of blood-borne 
diseases. Injection of stimulant drugs has been 
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associated with elevated levels of drug and sexual risk 
taking behaviours.
Nature and extent of health consequences
Data on the health consequences of α-PVP are mostly 
limited to the acute intoxications and deaths which are 
discussed above.
Long-term consequences of use
There is no information on the long-term consequences 
of α-PVP use.
Conditions under which the substance is obtained 
and used
It appears that α-PVP is sourced and used by individuals 
attempting to source the drug itself. Sources appear to 
include Internet retailers, bricks-and-mortar shops, and 
street level drug dealers. In addition, some users may be 
unaware that they have sourced and used α-PVP either 
because they have obtained it as ‘legal high’ products 
with no indication that it contains α-PVP or because it 
has been mis-sold on the illicit market as a drug such as 
MDPV or methamphetamine, or sold as ecstasy.
Based on the available data, it appears that α-PVP is 
used in the same environments as other 
psychostimulants. This would be typically (but not 
restricted to) home environments, pubs/bars and 
discotheques/nightclubs, and outdoor music festivals. In 
addition, α-PVP is likely to be used in some of the other 
environments used by problem drug users who inject 
opioids and stimulants.
I Social risks
 
Data on the social risks of α-PVP are limited.
| Individual social risks
There is no information on whether the use of α-PVP 
affects education or career, family or other personal or 
social relationships, including marginalisation.
|  Possible effects on direct social environment (e.g. neglect of family, violence)
There is no specific information on the possible effects 
of α-PVP on the direct social environment.
While there have been no clinical studies of the effects 
on α-PVP in humans, data from animal studies as well as 
from acute intoxications, deaths and self-reported user 
experiences suggest that the acute behavioural effects 
of α-PVP might bear some similarities to other 
psychostimulants such as cocaine, methamphetamine 
and MDPV.
|  Possible effects on society as a whole (public order and safety, acquisitive crime)
Data related to the social risk associated with the 
trafficking and distribution of α-PVP is limited. According 
to data provided by Europol, the seizure of two illicit 
production sites for α-PVP in Poland was linked to local 
football hooligans (Section 6). No further information is 
available.
| Economic costs (demands on healthcare)
Due to the lack of data, it is not possible at this time to 
estimate whether α-PVP is associated with greater 
healthcare costs than other stimulant drugs.
| Possible appeal to specific population groups
There is no specific data on the possible appeal of α-PVP 
to specific user groups. However, the available data 
suggests that α-PVP is used by recreational drug users 
as well as by problem drug users including those who 
inject stimulant and opioid drugs. Problem drug users 
are often marginalised. Overall, the extent of the 
possible appeal of α-PVP to these two broad groups of 
users is unknown. 
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I  Information on manufacturing, trafficking, distribution, and the level of involvement of organised crime
α-PVP has been available on the European Union drug 
market since at least February 2011. It has been 
detected in all 28 Member States (8).
More than 750 kg of α-PVP in powder form has been 
seized in Europe since 2011. In most cases α-PVP has 
been seized as a powder, but other forms including 
tablets have been detected.
In terms of trafficking and distribution, it appears that 
bulk, multi-kilogram quantities of α-PVP are imported 
into the European Union from China and then distributed 
across Europe. This includes a single seizure of almost 
260 kg in 2015. In addition to importation from China, 
two illicit production sites have been seized in Poland (in 
2013 and 2014) where multi-kilogram quantities of 
α-PVP were synthesised. The synthesis was supervised 
by trained chemists, and the laboratories were 
supported by suppliers, producers and distributors of 
chemicals. The companies involved operated their own 
websites selling and distributing α-PVP across Poland. 
This case demonstrates that the capability to 
manufacture α-PVP exists within the European Union.
In respect to the processing of α-PVP in Europe, Hungary 
reported that α-PVP was detected in two tablet 
manufacturing sites which were dismantled in 2013 and 
in 2014, respectively. The site seized in 2013 was 
a tableting unit where pentedrone tablets were 
produced; 24 908 tablets containing pentedrone and 
800 g of α-PVP in powder form were seized. In 2014, 
a tablet manufacturing site where pentedrone tablets 
were produced was also dismantled; in the storage 
location linked to this site, 1.5 kg of α-PVP in powder 
form was seized. According to Hungarian police in both 
these cases the suspects intended to produce tablets 
using the α-PVP powder.
Limited information is available in relation to the 
involvement of organised crime in the manufacture and/
or trafficking of α-PVP. Hungarian authorities reported 
that there are no established organised crime groups 
involved in the manufacture or trafficking of α-PVP. 
Latvian authorities reported that since 2014, a new trend 
has been observed in relation to the market in new 
psychoactive substances: a Latvian organised crime 
group was involved in the mixing and distribution of new 
(8) α-PVP has also been detected in Turkey and Norway. 
psychoactive substances in herbal form and in one such 
case, the herbal substance was mixed with α-PVP.
Some of the seizures of tablets by law enforcement that 
contained α-PVP showed a range of colours, markings 
and logos (9) consistent with ecstasy tablets. This raises 
the possibility that some of these tablets may have been 
designed to be sold as ecstasy on the illicit drug market.
I  Information on any assessment  in the United Nations system
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the 
medical, scientific and public health aspects of 
psychoactive substances under the Single Convention 
on Narcotic Drugs of 1961 and the Convention on 
Psychotropic Substances of 1971. At the time that the 
Joint Report (6) was prepared, the World Health 
Organization informed the EMCDDA that α-PVP was not 
currently under assessment nor had it been under 
assessment by the United Nations system. In November 
2015, the World Health Organization informed the 
EMCDDA that α-PVP was assessed at the Thirty-
Seventh Meeting of the Expert Committee on Drug 
Dependence that was held 16–20 November 2015. The 
outcome of the assessment has not yet been published.
I  Description of the control  measures that are applicable  in the Member States
Sixteen Member States (the Czech Republic, Estonia, 
Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Latvia, Lithuania, Poland, Romania, Slovenia, Sweden 
and the United Kingdom) reported that α-PVP is 
controlled under drug control legislation (10).
 § In the Czech Republic, α-PVP has been listed in 
Government Regulation No. 463/2013 Coll., (as 
amended) since 1 October 2015.
(9) It is common to find markings on tablets sold as ecstasy including 
those of popular cultural and iconic brands often having an 
association with quality. 
(10) Turkey and Norway also reported that α-PVP is controlled under drug 
control legislation. In Turkey, α-PVP is listed in the Law on Control of 
Narcotics No. 2313 adopted on 22 March 2012. In Norway, α-PVP is 
covered by the generic definition of cathinones in the Norwegian list of 
narcotics. 
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 § In Estonia, α-PVP has been listed in the Regulation 
No. 73 of the Minister of Social Affairs of 18 May 2005 
since 2 June 2014.
 § In Finland, α-PVP has been listed in the Narcotics Act 
373 of 2008 since 30 December 2013.
 § In France, α-PVP was added to the controlled narcotic 
substance list on 2 August 2012.
 § In Germany, α-PVP has been placed under schedule II 
(narcotics eligible for trade but not for medical 
prescription) of the Narcotic Substance Act, effective 
as of 17 July 2013.
 § In Greece, α-PVP is considered to be controlled under 
law 3459/2006 due to the fact that it has the same 
molecular weight and molecular formula as 
metazocine, an opioid analgesic classified in Table 
C of this law.
 § In Hungary, α-PVP is listed in Schedule 
A (psychotropic substances) of Act XXV of 1998 on 
human pharmaceuticals since 1 January 2015.
 § In Ireland, α-PVP is covered by the generic definition 
of controlled cathinones included in the Misuse of 
Drugs Act.
 § In Italy, α-PVP is also controlled generically, as 
a derivative of 2-amino-1-phenyl-1-propanone, under 
the Decree of the President of the Republic 309/90 
since 29 December 2011.
 § In Latvia, α-PVP is controlled generically according to 
Cabinet Regulation 847 ‘Regulations regarding 
narcotic substances, psychotropic substances and 
precursors to be controlled in Latvia’.
 § In Lithuania, α-PVP is controlled as a cathinone 
derivative by an Amendment to the Law on the 
Control of Narcotic Drugs and Psychotropic 
Substances adopted in 2010.
 § In Poland, α-PVP is listed in Schedule IV of the Act of 
24 April 2015 amending the Act of Counteracting 
Drug Addiction since 1 July 2015.
 § In Romania, α-PVP is controlled by Law 143/2000 on 
preventing and combating trafficking and illicit drug 
use and it is listed in Table I of the law 339/2005 on 
the legal regime of plants, narcotic and psychotropic 
substances and preparations.
 § In Slovenia, α-PVP was included by the Decree on 
amending the Decree on Classification of Illicit Drugs, 
Official Gazette of RS No. 45/2014 since July 2014.
 § In Sweden, α-PVP comes under the Narcotic Drugs 
Control Act since 1 February 2013.
 § In the United Kingdom, α-PVP was included in the 
generic definition of substituted cathinone derivatives 
placed under the Misuse of Drugs Act 1971 in April 
2010.
Four Member States (Austria, Cyprus, Portugal and 
Slovakia) reported that α-PVP is controlled under 
legislation prohibiting the unauthorised supply of 
defined or qualifying new psychoactive substances.
 § In Austria, α-PVP is categorised as member of the 
‘amino phenyl ethanone’ (i.e. cathinone) generic group 
in the New Psychoactive Substances Act.
 § In Cyprus, α-PVP also falls under the generic 
definition of a cathinone under specific NPS 
legislation as of 24 June 2011.
 § In Portugal, α-PVP is listed as controlled under 
Decree-Law 154/2013 of 17 April 2013.
 § In Slovakia, α-PVP is listed as a ‘hazardous substance’ 
as of 1 October 2013.
In the Netherlands, the sale of α-PVP in consumer 
amounts is treated as being a medicinal product and 
must comply with medicines legislation.
Seven Member States (Belgium, Bulgaria, Croatia, 
Denmark, Luxembourg, Malta and Spain) reported that 
α-PVP is not subject to control measures at the national 
level. Belgium reported that it has started the process to 
control the substance under drug control legislation.
I  Options for control and the possible consequences of the control measures
Under Article 9.1 of the Council Decision, the option for 
control that is available at European Union level is for the 
Member States to submit the new psychoactive 
substance α-PVP to control measures and criminal 
penalties, as provided for under their legislation, by 
virtue of their obligations under the Convention on 
Psychotropic Substances of 1971. There are no studies 
on the possible consequences of such control measures 
on α-PVP. If this option of control is pursued, the 
Committee considers that the following consequences 
are possible. Some of these may apply to any new 
psychoactive substance.
 § This control option could be expected to limit the 
availability of α-PVP and hence the further expansion 
of the current open trade in this substance.
 § A health consequence that might result from this 
control option is the benefit brought about by the 
presumed reduction in availability and use. In this 
respect it is noteworthy that the People’s Republic of 
China placed α-PVP under national drug control 
legislation on 1 October 2015.
 § This control option could facilitate the detection, 
seizure and monitoring of α-PVP related to its 
unlawful manufacture, trafficking and use. In so doing, 
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it could facilitate cooperation between the judicial 
authorities and law enforcement agencies across the 
European Union.
 § This control option would imply additional costs for 
the criminal justice system, including forensic 
services, law enforcement and the courts.
 § This control option could lead to replacement with 
other (established or new) psychoactive substances, 
which may in themselves have public health 
consequences and social risks.
 § This control option could create an illicit market in 
α-PVP with the increased risk of associated criminal 
activity, including the involvement of organised crime.
 § This control option could impact on both the quality/
purity and price of any α-PVP still available on the 
illicit market. The extent to which this will impact on 
public health, criminality, or levels of use, is difficult to 
predict.
 § It is difficult to predict the impact of this control option 
on current or future research by the pharmaceutical 
or chemical industries.
 § In order to examine the consequences of control, the 
Committee wishes to note that it will be important to 
monitor for the presence of α-PVP on the market 
post-control, should this control option be pursued.
 § Aside from the option for control under those 
stipulated in Article 9.1 of the Council Decision, other 
options for control may be available to Member 
States. These may include restricting the importation 
and supply of the substance as some Member States 
have already done.
I Conclusions
The new psychoactive substance 1-phenyl-2-(pyrrolidin-
1-yl)pentan-1-one (α-PVP) is a potent psychostimulant. 
α-PVP is structurally related to cathinone, pyrovalerone 
and MDPV, which are listed in the United Nations 
Convention on Psychotropic Substances of 1971.
α-PVP has been available on the drug market in the 
European Union since at least February 2011 and has 
been detected in all 28 Member States. α-PVP is 
typically administered by nasal insufflation, injection and 
orally.
In vitro data suggests that α-PVP acts predominantly as 
an inhibitor of dopamine (DA) uptake at the dopamine 
transporter (DAT) and norepinephrine (NE) uptake at the 
norepinephrine transporter (NET). α-PVP has similar or 
even greater potency at DAT and NET but not the 
serotonin transporter (SERT) compared to cocaine and 
methamphetamine. This is a mode of action that is also 
known to occur with other psychostimulants with 
monoamine uptake properties, such as MDPV.
The effects of α-PVP in animals are in alignment with 
those observed with other psychostimulants such as 
MDPV, cocaine and methamphetamine. The 
neurochemical features associated with α-PVP include 
detection of increased levels of extracellular dopamine 
levels in mice striatum using microdialysis, and 
behavioural features such as locomotor activation, and 
full substitution for the discriminative stimulus effects of 
cocaine and methamphetamine. Similar to MDPV, α-PVP 
was shown to act as a reinforcer when studied in animal 
models of reinforcement.
Data from non-clinical studies suggests that α-PVP may 
have an abuse liability and possibly a dependence 
potential in humans.
Limited information available from acute intoxications 
and deaths as well as from user websites suggests that 
the physiological and psychological effects of α-PVP 
might be similar to other psychostimulants such as 
MDPV.
The available data suggests that α-PVP is used by 
recreational drug users and problem drug users. In the 
latter case, this includes individuals who inject stimulant 
and opioid drugs. However, no further information on the 
size and demand and the characteristics of these groups 
of people is available. There is no specific information on 
the social risks that may be related to α-PVP.
One hundred and ninety one acute intoxications have 
been reported where α-PVP was detected in biological 
samples taken from the patients. Case level data was 
available for 29 of these cases. The adverse symptoms 
and signs were generally consistent with 
sympathomimetic toxicity.
One hundred and fifteen deaths have been reported 
where α-PVP was detected post-mortem. In 20 % of 
these cases α-PVP was reported as either the cause of 
death or that it contributed to the death; in five (4 %) of 
these cases α-PVP was the only substance detected.
There is limited information to suggest the potential 
involvement of organised crime in the manufacture, 
distribution (trafficking) and supply within the European 
Union. The chemical precursors and the synthetic routes 
used to manufacture the α-PVP detected within the 
European Union are unknown. Most of the α-PVP on the 
European drug market appears to originate from 
chemical companies based in China. However, two 
clandestine laboratories have also been seized within 
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one Member State that were producing α-PVP in 
multi-kilogram amounts.
α-PVP has no recognised medical (human or veterinary) 
use in the European Union nor, it appears, elsewhere. 
There are no indications that α-PVP may be used for any 
other purpose aside from as an analytical reference 
standard and in scientific research.
α-PVP is not listed for control in the Single Convention 
on Narcotic Drugs of 1961 nor in the Convention on 
Psychotropic Substances of 1971. α-PVP is currently 
under assessment by the United Nations system.
Sixteen Member States control α-PVP under drug 
control legislation and five Member States control α-PVP 
under other legislation.
As for any new psychoactive substance, many of the 
questions related to α-PVP that are posed by the lack of 
data on the risks to individual health, risks to public 
health, and social risks, could be answered through 
further research. Areas where additional information 
would be important include studies on: rationale for use, 
prevalence and patterns of use (including targeted 
studies that examine user groups, increased risks of 
infectious diseases and other risk behaviours); the 
market; chemical profiling; receptor binding and 
functional activity; metabolic pathways; behavioural 
effects; acute and chronic toxicity; the potential 
interaction between α-PVP and other substances; the 
dependence and abuse potential; and the public health 
risks associated with its use.
The Committee notes that a decision to control α-PVP 
has the potential to bring with it both intended and 
unintended consequences. Potential intended 
consequences include reduced levels of availability and 
ultimately use. This may reduce the health and social 
risks and consequences arising from the use of α-PVP. It 
is important to recognise that a potential unintended 
consequence of control may be the manufacture and 
availability of other substances. Although there is limited 
information on the human (psycho)pharmacological 
effects, chemically analogous substances that may 
replace α-PVP are already being sold on the drug market. 
The implementation of control measures may also lead 
to the criminalisation of those who continue to use this 
substance with the possible attendant risks of socio-
economic stigmatisation and marginalisation. Finally, 
control measures should not inhibit the gathering and 
dissemination of accurate information on α-PVP to 
users, practitioners, policymakers and decision-makers.
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ANNEX 1
Technical report on 1-phenyl-2-
(pyrrolidin-1-yl)pentan-1-one 
(α-pyrrolidinovalerophenone, α-PVP)
Dr Simon Brandt, Dr Simon Elliott
I Data sources
The information in this technical report is derived from:
 § data reported by the Member States to the EMCDDA 
and Europol in accordance with Council Decision 
2005/387/JHA on the information exchange, risk 
assessment and control of new psychoactive 
substances (11); and,
 § data collected through systematic searches of open 
source information, including the scientific and 
medical literature, patents, official reports, grey 
literature, Internet drug discussion forums and related 
websites, and online vendors selling α-PVP.
I Note
It is important to note when interpreting the data on 
self-reported user experiences that is provided in this 
report, it is not possible to confirm the specific 
substance(s) used; similarly it is also not possible to 
confirm the strength, purity, dose/amount, etc., used. In 
addition, the information provided on user websites and 
from specific user groups may not necessarily be 
representative of other users of α-PVP and should be 
regarded as illustrative only.
(11) OJ L 127, 20.5.2005, p. 32. 
I  Section A. Physical, chemical, pharmaceutical and pharmacological information
|  A1. Physical, chemical and  pharmaceutical information
A1.1. Physical and chemical description (including 
methods of synthesis, precursors, impurities if 
known — type and level)
Chemical description and names
1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-PVP) is 
a synthetic derivative of the naturally occurring stimulant 
cathinone, which is one of the psychoactive principles of 
the khat plant (Catha edulis Forsk). Cathinone is 
controlled under the United Nations Convention on 
Psychotropic Substances, 1971 (Schedule I).
Pyrrolidine cathinone derivatives such as α-PVP — 
where the nitrogen atom is part of a pyrrolidine ring — 
share the same structural skeleton as pyrovalerone and 
MDPV (Figure 1). The desmethyl analogue of α-PVP 
gives rise to pyrovalerone (1-(4-methylphenyl)-2-(1-
pyrrolidinyl)pentan-1-one), which is controlled under the 
United Nations Convention on Psychotropic Substances, 
1971 (Schedule IV). α-PVP is also structurally related to 
MDPV (3,4-methylenedioxypyrovalerone) (12) that was 
risk-assessed by the Scientific Committee of the 
EMCDDA in April 2014 (EMCDDA (2014)). In March 
2015, it was decided that MDPV should be controlled 
under the Convention on Psychotropic Substances, 
(12) The origin for the common name is indicated by underlining the 
relevant letters in the systematic chemical name.
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1971 (Schedule II) (Commission on Narcotic Drugs, 
2015). The control entered into force in November 2015.
α-PVP contains a stereogenic centre thus allowing for 
the existence of a pair of enantiomers, (S)-α-PVP and 
(R)-α-PVP.
Lower and higher homologues of α-PVP currently 
monitored by the EMCDDA are: 
α-pyrrolidinopropiophenone (α-PPP), 
α-pyrrolidinobutyrophenone (α-PBP), alpha-
pyrrolidinohexanophenone (α-PHP), 
α-pyrrolidinoenanthophenone (α-PEP or α-PHPP or PV8), 
α-pyrrolidinooctanophenone (α-POP or PV9) and α-PNP 
(alpha-pyrrolidinononaphenone), respectively. 
Substituted derivatives of α-PVP which are being 
monitored by the EMCDDA are: 4-Br-α-PVP, 4-Cl-α-PVP, 
4-F-α-PVP, 4-MeO-α-PVP and 3,4-DMeO-α-PVP (13). 
Substituted derivatives of lower and higher homologues 
of α-PVP which are being monitored by the EMCDDA 
are: 4-Cl-α-PPP, MPPP (4-Me-α-PPP), MOPPP (4-MeO-
α-PPP), 4F-PBP, MPBP (4-Me-α-PBP), 4-MeO-α-PBP, 
4-F-α-PHP, MPHP (4-Me-α-PHP), 3,4-DMeO-α-PHP, 
4-MeO-α-PEP and 4-MeO-α-POP (4-MeO-α-PV9).
On 1 October 2015, the People’s Republic of China 
placed α-PVP under national drug control legislation. 
α-PBP, α-PHP, α-PEP, 4-F-α-PVP, 4-MeO-α-PVP, 
α-pyrrolidinovalerothiophenone (α-PVT) were also 
controlled. All of these substances are monitored by the 
EMCDDA. 
The common name for α-PVP is alpha-
pyrrolidinovalerophenone.
The systematic IUPAC name for α-PVP is 1-phenyl-2-
(pyrrolidin-1-yl)pentan-1-one.
Chemical Abstract Service (CAS) registry numbers are 
given in Table 1. Commonly encountered names and 
codenames used for α-PVP are given in Table 2.
(13) Derivatives substituted with a cycle on the phenyl ring, such as 
naphyrone, 1-naphyrone, 5-DBFPV (5-dihydrobenzofuranpyrovalerone), 
MDPV and TH-PVP have been excluded from the list. The number 
indicates the position(s) of the phenyl ring which are substituted with 
the substituents: bromo (Br), chloro (Cl), fluoro (F), methyl (M and Me) 
and methoxy (MeO) or dimethoxy (DMeO).
FIGURE 1
The molecular structure, molecular formula, molecular 
weight, and monoisotopic mass of α-PVP. The molecular 
structure, molecular formula, molecular weight and 
monoisotopic mass of MDPV and pyrovalerone are 
provided for comparison. Chiral centres are denoted by 
an asterisk on the molecular structures.
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TABLE 1
Chemical Abstract Service (CAS) registry 
numbers for α-PVP
CAS Registry Numbers Variant
14530-33-7 Free base
5485-65-4 Hydrochloride salt
14859-27-9 Tartrate salt
14859-28-0 Maleate salt
14995-79-0 Citrate salt
100175-06-2 Hydrogen maleate salt
16121-74-7 Sulfate salt
13415-49-1 Sulfate salt (1:1)
1346599-00-5 d
8
-Free base
1781744-06-6 d
8
-Hydrochloride salt
TABLE 2
Chemical names, common names and codenames 
reported for α-PVP
1-Phenyl-2-(1-pyrrolidinyl)-1-pentanone
1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-on (German)
1-Fenyyli-2-(1-pyrrolidinyyli)-1-pentanoni (Finnish)
2-(1-Pyrrolidinyl)-valerophenone
2-Pyrrolidinovalerophenone
2-(1-Pyrrolidinyl)-valerophenone
2-(Pyrrolidin-1-yl)phenylpentan-1-one
2-Pyrrolidin-1-yl-1-phenylpentan-1-one
α-Pyrrolidinopentiophenone
α-Pyrrolidinovalerophenone
α-Pyrrolidiinivalerofenoni (Finnish)
α-Pyrrolidinovalerophenon (German)
Desmethyl pyrovalerone
Prolintanone
β-keto-Prolintane
Pyrodilyl ketone
α-Pyrrolidino ketone
alpha-PVP, alfa-PVP, a-PVP, A PVP, PVP
α-2
CHEMBL205082
MFCD24386810
O-2387
Reported street names for α-PVP include: ‘grind’ 
(Belgium), ‘flakka’ (Croatia, Cyprus, the United Kingdom, 
and Turkey), ‘gravel’ (Cyprus and Turkey), ‘crystal love’ 
(Finland), ‘Pure NRG’ (Germany), ‘Snow Blow’ (Ireland) 
and ‘vanilla sky’ (Malta).
The following labelled ‘legal high’ products have been 
reported to contain α-PVP: ‘Yayo soft’, ‘Yayo 
experimental’ and ‘1NRG’ (Belgium); ‘Ocean Breath’ 
(Cyprus); ‘Guarana Coco jumbo’, ‘Cherry Coco jumbo’, 
‘ILOVEPARADE’ and ‘SENSATION’ (Czech Republic); 
‘NRG3’, ‘Energy 3’ and ‘PV-11’ (France); ‘Pure NRG’ 
(Germany); ‘A-1 PUP’ (Italy); ‘E21’, ‘G-Y’, ‘S1 Turbo’ and 
‘GIE-ES M’ (Poland); ‘Sextacy’, ‘Bloom’, ‘Quick Silver’, 
‘Formula 3’, ‘Ivory’ and ‘Vanila [sic] Sky’ (Portugal); 
‘Doves’, ‘Fire Ball’, ‘Green Speed’, ’Knock out’, ‘Max’, 
‘Speedway’, ‘Total speed’ and ‘Ultra Violet Exclusive’ 
(Slovakia); and ‘NRG-3’, ‘Energy - 3 (NRG-3)’ and 
‘Spellweaver’ (United Kingdom). Some of these products 
are marketed as ‘research chemicals’, ‘bath salts’, ‘plant 
food’ or ‘insect repellents’ in order to circumvent 
legislation.
Identification and analytical profile
α-PVP was first identified in Germany in 2005 (Westphal 
et al., 2011). Mass spectral data for α-PVP obtained from 
metabolism studies were published in 2009 (Sauer et 
al., 2009). Since 2011, the increased availability of 
α-PVP has facilitated the development of a range of 
analytical methods that are routinely used for its 
characterisation and detection in sample matrices 
commonly encountered in forensic and clinical 
investigations (Table 3). The Marquis and Mecke tests 
were reported to give a ‘clear’ and ‘grey/black’ reaction, 
respectively (Reagent-base.net, 2015).
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TABLE 3
Representative examples of analytical methods applied to the detection and/or characterisation of α-PVP which have 
been published in the scientific literature (14)
GC-MS Reference
Metabolism studies in vivo (male Wistar rats) and in vitro Sauer, et al. (2009)
Analysis of a branded product Elie et al. (2013)
Detection in biofluids Saito et al. (2013)
Characterisation of synthesized material Tsujikawa et al. (2013)
Detection in authentic urine specimens Namera et al. (2014)
Detection in authentic urine specimens Uralets et al. (2014)
Method development using supplied samples Fujii et al. (2015)
GC-MS and LC-MS
Detection in biofluids Namera et al. (2013b)
Detection in biofluids Hasegawa et al. (2014)
Analysis of branded products Leffler et al. (2014)
Detection in authentic urine specimens Shima et al. (2014)
Metabolism studies in vitro and application to authentic biofluids samples Friscia et al. (2015)
Detection in biofluids and powdered material Sykutera et al. (2015)
GC-MS and other methods of analysis
Characterisation of synthesized material (incl. NMR and FTIR) Casale and Hays (2012)
Characterisation of supplied samples (incl. LC-UV, FTIR and IMS) Armenta et al. (2015)
LC-MS
Analysis of branded products Shanks et al. (2012)
Method development for oral fluid analysis and application to test samples obtained from 
subjects
Amaratunga et al. (2013)
Method development for urine analysis and application to authentic urine specimens Concheiro et al. (2013)
Detection in biofluids and powdered sample by FTIR and GC-MS Eiden et al. (2013)
Detection in biofluids Marinetti and Antonides (2013)
Method development for hair analysis and application to authentic hair specimens Namera et al. (2013a)
Detection in biofluids Shanks et al. (2013)
Metabolism studies in-silico and in vitro and application to authentic urine specimens Tyrkkö et al. (2013)
Characterisation of supplied standards Fornal (2014)
Detection in biofluids Knoy et al. (2014)
Analysis of products purchased from shops Schneir et al. (2014)
Use as internal standard for analyses of biofluids Wurita et al. (2014)
Detection in wastewater samples Borova et al. (2015)
Method development for urine analysis and application to authentic urine specimens Concheiro et al. (2015)
In vitro metabolism studies Negreira et al. (2015)
Detection in biofluids Yap and Drummer (2015)
Miscellaneous methods of analysis
Characterisation of synthesized material (ESI-in-source CID-MS) Power et al. (2012)
Method development for blood and application to authentic blood specimens
(MALDI-TOF-MS and Q-TOF-MS/MS)
Minakata et al. (2014)
Chiral analysis of products obtained from Internet retailers (LC-UV) Taschwer et al. (2014)
Analysis of reference material (13C-NMR) Uchiyama et al. (2014)
Characterisation of synthesized samples (FTIR and NMR) Guha et al. (2015)
(14) GC: gas chromatography; MS: mass spectrometry; LC: liquid chromatography (various forms); NMR: nuclear magnetic resonance spectroscopy; FTIR: 
Fourier transform infrared spectroscopy; ESI: electrospray ionisation; CID: collision-induced dissociation; UV: ultraviolet spectroscopy; MALDI: 
matrix-assisted laser desorption/ionisation; TOF: time-of-flight; MS/MS: tandem mass spectrometry.
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TABLE 4
Melting points reported for α-PVP
Salt Melting point Reference
Hydrochloride 173 °C (ethanol/
diethyl ether)
Madras et al. (2005), 
Meltzer et al. (2006)
Hydrochloride 162 °C Seeger (1966), 
Seeger (1967)
Hydrochloride 162 °C (acetone) Dr. Karl Thomae 
GmbH (1963)
Hydrochloride 104–106 °C / 
169–170 °Ca
Heffe (1966a)
Acid sulfate 140 °C 
(isopropanol)
Dr. Karl Thomae 
GmbH (1963)
Tartrate 148–149 °C Seeger (1966)
Tartrate 148–149 °C 
(isopropanol)
Dr. Karl Thomae 
GmbH (1963)
Maleate 131 °C Seeger (1966)
Maleate 131 °C (acetone) Dr. Karl Thomae 
GmbH (1963)
Hydrogen maleate 131 °C Seeger (1967)
Hydrogen maleate 131 °C (acetone) Dr. Karl Thomae 
GmbH (1963)
Citrate 88 °C Seeger (1966)
Citrate 88 °C (acetone) Dr. Karl Thomae 
GmbH (1963)
a Described as anhydrous salt form.
Physical description
The hydrochloride salt of α-PVP is described as a white, 
crystalline powder. Its solubility is reported as: ~10 mg/
mL in PBS (pH 7.2); ~20 mg/mL in EtOH; ~10 mg/mL in 
DMSO and ~3 mg/mL in DMF, respectively (Cayman 
Chemical Company, 2015). Earlier work carried out in the 
1960s reported a number of melting points (Table 4). 
The boiling point was determined at 113 °C at 0.15 mm/
Hg (Dr. Karl Thomae GmbH, 1963; Seeger, 1966, 1967).
Racemic α-PVP is commercially available as analytical 
reference material.
There is no information on the isomeric composition of 
the samples of α-PVP detected within the European 
Union, which in part may reflect the fact that 
stereochemical analysis is not routinely undertaken in 
forensic laboratories.
Methods and chemical precursors used for the 
manufacture of α-PVP
No information was reported to the EMCDDA about the 
chemical precursors or manufacturing methods used to 
make the α-PVP which has been detected on the drug 
market in Europe.
Methods for the production of α-PVP are documented in 
the scientific literature and include α-halogenation of 
1-phenylpentan-1-one (valerophenone) followed by 
amination with pyrrolidine (Dr. A. Wander S.A, 1963), 
(Dr. Karl Thomae GmbH, 1963). This particular route is 
particularly useful for the preparation of cathinone 
derivatives in general. Other routes have also been 
reported and include the use of Grignard conditions 
(Casale and Hays, 2012), (Dr. A. Wander S.A, 1963), or 
reaction of an epoxide intermediate with pyrrolidine 
(Dr. A. Wander S.A, 1963; Heffe, 1966b; Heffe, 1966c), or 
involvement of the ephedrine-type precursor 
(Dr. A. Wander S.A, 1963; Guha, et al., 2015; Heffe, 1966a).
Typical impurities encountered in seized samples
Detailed information available with regards to route-
specific by-products produced during the synthesis of 
α-PVP is currently not available.
There are no quantitative data available on the impurities 
detected in seized and collected samples reported to 
the EMCDDA.
Information on purity, which was available from 
17 seizures reported to the EMCDDA, ranged from 23 % 
(2 seizures) to over 95 % (8 seizures).
In around 35 % of the seizures reported to the EMCDDA, 
α-PVP was found in combination with other substances 
(Section D3.1).
Most of the powder seizures detected were described as 
white or off-white in colour; in one case from Spain the 
powder was described as ‘black rock powder’.
A1.2. Physical/pharmaceutical form
Reports of seizures and collected samples have noted 
that α-PVP has typically been detected in the form of 
powders as well as tablets (Section C). α-PVP has also 
been detected in powder-filled capsules, vegetable 
material, liquids, blotters (small pieces of paper 
impregnated with α-PVP for sublingual/buccal 
administration) and in jelly gums.
It is worth noting that α-PVP and a number of ring-
substituted derivatives were featured in a number of 
patents in the early 1960s that investigated their 
potential use as central nervous stimulants and 
antihypotensive/vasopressor agents in humans. The 
suggested formulations for these substances included 
tablets (up to 60 mg), suppositories (1 – 60 mg), dragées 
(30 mg), ampules (10 mg/2 mL) and drops (60 mg/mL), 
respectively (Dr. A. Wander S.A, 1963; Dr. Karl Thomae 
GmbH, 1963; Seeger, 1966, 1967).
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A1.3. Route of administration and dosage
Route of administration
Data reported to the EMCDDA as well as from user 
websites suggests that typical routes of administration 
of α-PVP are snorting (nasal insufflation), oral (ingestion), 
and injection (including intravenous route). Other 
reported routes, include sub-lingual, smoking/inhalation, 
and rectal.
Dosage
Self-reported user experiences have noted that in some 
individuals the ‘threshold’ level for α-PVP (that is the 
dose required to induce an effect) may occur with oral 
doses of 1–2 mg; ‘strong’ effects were reported with oral 
doses of 20–25 mg. Nasal insufflation was considered 
a more potent method of administration based on the 
doses needed to classify as ‘threshold’ levels and 
beyond (Psychonautwiki, 2015).
Data on the dose of α-PVP used was available in two 
analytically confirmed acute intoxications reported by 
Sweden. In one case, an oral dose of 15–20 mg was 
used; in another case, 330 mg was used (route 
unknown).
France reported a dose of 20–30 mg used by two 
individuals that had injected α-PVP intravenously.
|  A2. Pharmacology, including  pharmacodynamics and pharmacokinetics
Pharmacodynamics
α-PVP and closely related ‘α-pyrrolidino-valerophenones’ 
have been studied to some extent as part of 
pharmaceutical investigations designed to explore their 
hypertensive and central nervous system stimulant 
effects. Published research studies were limited until the 
early 2000s when an extensive set of pyrovalerone 
derivatives were studied in vitro for their interactions 
with monoamine transporters (Madras, et al., 2005; 
Meltzer, et al., 2006).
Although there is no information about the action of the 
optical isomers of α-PVP, it is interesting to note that in 
the case of pyrovalerone — the 4-methylphenyl 
analogue of α-PVP — activity was reported to reside 
with the (S)-isomer (Meltzer, et al., 2006).
No studies were identified that have investigated the 
pharmacodynamics of α-PVP in humans.
In vitro pharmacology
Data suggests that α-PVP acts predominantly as an 
inhibitor of dopamine (DA) uptake at the dopamine 
transporter (DAT) and norepinephrine (NE) uptake at the 
norepinephrine transporter (NET). This mode of action is 
also known to occur with psychostimulants such as 
cocaine and MDPV, which are known to affect 
monoamine uptake (Table 5).
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In vivo pharmacology
Information available from animal studies suggests that 
the effects of α-PVP are in alignment with those 
observed with other psychostimulants such as MDPV, 
cocaine and methamphetamine where the role of 
catecholaminergic mechanisms are well established. As 
summarised in Table 6, the neurochemical and 
behavioural features associated with α-PVP include 
locomotor activation, detection of increased levels of 
extracellular dopamine levels in mice striatum using 
microdialysis, and full substitution for the discriminative 
stimulus effects of cocaine and methamphetamine. 
Similar to MDPV, α-PVP was shown to act as a reinforcer 
when studied by intravenous self-administration in rats 
(Table 7). Stereotypy and bizarre behaviour have been 
observed in animals, especially at higher doses. This 
finding is consistent with a range of other 
psychostimulants.
TABLE 5
In vitro uptake inhibition and binding data for α-PVP at the dopamine transporter (DAT), norepinephrine transporter 
(NET), and, serotonin transporter (SERT)
Uptake inhibition a Affinity b Reference
DAT
IC
50
/nM
NET
IC
50
/nM
SERT
IC
50
/nM
DAT
K
i
/nM
NET
K
i
/nM
SERT
K
i
/nM
52.3 56.0 -- 33.7 199 > 10,000 Madras, et al. (2005) c, Meltzer, et al. (2006)
205 d -- -- -- -- -- Kolanos et al. (2013) e
12.8 14.2 > 10,000 -- -- -- Marusich et al. (2014) f
17.5 -- > 10,000 -- -- -- Kolanos et al. (2015)
40 20 > 100,000 7 60 > 30,000 Rickli et al. (2015) g
a  Meltzer, et al. (2006): HEK293-hDAT, HEK293-hNET, HEK293-hSERT ([3H]DA, [3H]NE, [3H]5-HT); Kolanos, et al. (2013): HEK-hDAT ([3H]DA); Marusich, 
et al. (2014): rat brain synaptosomes (5 nM [3H]DA, [3H]NE, [3H]5-HT); Kolanos, et al. (2015): rat brain synaptosomes (5 nM [3H]DA, [3H]5-HT); Rickli, et 
al. (2015): HEK293-hDAT, HEK293-hNET, HEK293-hSERT (5 nM [3H]DA, [3H]NE, [3H]5-HT).
b  Meltzer, et al. (2006): HEK293-hDAT, HEK293-hNET, HEK293-hSERT ([125I]RTI-55, 40 – 80 pM)); Rickli, et al. (2015): HEK293-hDAT, HEK293-hNET, 
HEK293-hSERT (N-methyl-[3H]-nisoxetine and indatraline (NET), [3H]citalopram and indatraline (SERT), [3H]WIN35,428 and indatraline (DAT). A ‘DAT 
affinity’ value of 13 nM was also given in Madras, et al. (2005)
c  Uptake data for cocaine (Meltzer, et al., 2006) (IC
50
/nM): DAT = 461; NET = 378; SERT = 494. Affinity data for cocaine (Meltzer, et al., 2006) (K
i
/nM): 
DAT = 432; NET = 2,150; SERT = 358.
d  Additional experiments (two-electrode voltage clamp; −60 mV using Xenopus oocytes expressing hDAT to illustrate inhibitor-like behaviour. Following 
α-PVP exposure (10 μM), DA (5 μM) elicited hDAT-mediated inward current 25.4 % relative to amplitude obtained from first DA application (5 μM).
e  Affinity data for MDPV (Kolanos, et al., 2013): DAT K
i
 = 135 nM.
f  Marusich, et al. (2014): Uptake data (IC
50
/nM). MDPV: DAT = 4.1; NET = 25.9; SERT > 10,000; cocaine: DAT = 211; NET = 292; SERT = 313; ampheta-
mine; DAT = 93; NET = 67; SERT = 3,418.
g  Rickli, et al. (2015): Uptake data (IC
50
/nM). MDPV: DAT = 50; NET = 40; SERT = 9,600; methamphetamine: DAT = 1,100; NET = 140; SERT = 18,000; 
amphetamine: DAT = 1,300; NET = 70; SERT = 35,000. 
Affinity data (Rickli, et al., 2015) (K
i
/nM). MDPV: DAT = 10; NET = 8; SERT = 2,900; methamphetamine: DAT = 1,800; NET = 3,000; SERT = 24,600.
h  Receptor binding profiles: 
K
i
 (μM): 5-HT
1A
 = 5.2; 5-HT
2A
 > 13; 5-HT
2C
 > 13; α
1A
 > 15; α
2A
 >20; D
1
 > 12; D
2
 > 10; D
3
 > 17; H
1
 > 13; TA
1rat
 = 16.3; TA
1mouse
 > 20; TA
1human
 > 20. 5-HT
2B
 
Activation potency (EC
50
) using HEK293-h5-HT
2B 
and
 
FLIPR assay > 20 μM and no activation.
h  [3H]-8-OH-DPAT and indatraline (5-HT
1A
), [3H]ketanserin and spiperone (5-HT
2A
), [3H]mesulergine and mianserin (5-HT
2C
), [3H]prazosin and risperidone 
(α1 adrenergic receptor), [3H]rauwolscine and phentolamine (α2 adrenergic receptor), [3H]SCH 23390 and butaclamol (DA
D1
), [3H]spiperone and 
spiperone (DA
D2
 and DA
D3
), [3H]pyrilamine and clozapine (H
1
) and [3H]-RO5166017 and RO5166017 (TA
1
).
TABLE 6
In vivo neurochemistry data for α-PVP
In vivo pharmacology (neurochemistry / physiology) Reference
DAT occupancy (rhesus monkeys): a 64 % based on positron emission tomography imaging; 
intravenous injection following pre-treatment with [11C]WIN 35,428 ([11C]CFT).
Madras, et al. (2005)
Microdialysis: b oral administration of α-PVP (25 mg/kg) and methamphetamine (5 mg/kg) led to 
significant increase in dopamine levels in dialysate samples (striatum). α-PVP showed shorter onset 
than methamphetamine but less pronounced concentration levels: ~600 % DA increase for 
methamphetamine vs. ~ 350 % DA increase at 20 min post-administration.
Kaizaki et al. (2014)
Thermoregulation: c modest, but consistent; dose-dependent hypothermic alteration ~0.75 °C up to 
3 hours after dosing.
Aarde et al. (2015)
a  Comparison of positron emission tomography imaging pre- and post-drug session (cerebellum) based on reduced [11C]WIN 35,428 binding one hour or 
longer after administration.
b  Balb/c male mice (8 weeks old). Extracellular dopamine levels determined in dialysate and collected for 120 min (12 measurements) following oral 
administration of α-PVP (25 mg/kg), methamphetamine (5 mg/kg) or water (10 mL/kg).
c  Male Wistar rats; room conditions 21 °C, single housing; radiotelemetry, data collection for 180 min following α-PVP administration 
(1, 5.6 and 10 mg kg, i.p.).
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TABLE 7
In vivo behavioural data for α-PVP
Behavioural pharmacology Reference
Locomotor activity
Oral administration of α-PVP (25 mg/kg) and methamphetamine (5 mg/kg) as a positive control. 
a Earlier and more pronounced onset observed with α-PVP (10 min) and considered “stronger”; 
effects also considered “more profound” than those observed for methamphetamine. Both 
substances displayed significant increases in locomotor activity based on distance travelled in 
metres. Administration of D
1
 receptor antagonist or a D
2
 receptor antagonist before α-PVP treatment 
led to attenuated distance travelled. Mean reduction (0−30 min) to 43 % (D
1
) and 54 % (D
2
); 
attenuation also observed in the 30−60 min time slot although less pronounced.
Kaizaki, et al. (2014)
Significant increases in activity over entire 60 min session at 3.0−10.0 mg/kg) and 20−50 min at 1 
mg/kg following α-PVP injection. b Increases of cumulative beam breaks considered significant at 
3.0 and 10 mg/kg. Administration of D
1
 receptor antagonist before α-PVP treatment led to 
significant reduction in total beam breaks with a main effect of pre-treatment at 3.0 mg/kg α-PVP. 
Doses needed to significantly increase locomotor activity during the first 10-min bin were lower 
than those for cocaine. Pre-treatment with a D
1
 receptor antagonist attenuated locomotor activity.
Marusich, et al. (2014)
Peak locomotor responses observed at 1.0 mg/kg and lasted ~2 h. Locomotor stimulant effects very 
similar to MDPV; α-PVP showed rebound of activity 2 h after injection of 5.6 mg/kg dose. c
Aarde, et al. (2015)
Time- and dose-dependent effects from 2.5 to 25 mg/kg; stimulant effects with 2.5, 5, and 10 mg/
kg observed within 10 min lasting 240–290 min. Stimulant effects not observed in the first 60 min at 
25 mg/kg and lasted 280 min. d
Gatch et al. (2015)
Drug discrimination
Full substitution for discriminative stimulus effects of cocaine and methamphetamine; slope of 
α-PVP dose effect in cocaine-trained rats substantially shallower than dose-effect curve determined 
for methamphetamine-trained animals. e
Gatch, et al. (2015)
Full substitution observed for training dose of methamphetamine; total drug-lever responses 
reached 88.6 % at 2.0 mg/kg; potency differences expressed as ED50 values: methamphetamine = 
0.3 mg/kg; α-PVP = 0.7 mg/kg; cocaine = 3.3 mg/kg; control response rates were significantly 
reduced at doses of 1.0 mg/kg (methamphetamine), 2.0 mg/kg (α-PVP) and 8.0 mg/kg (cocaine). f
Naylor et al. (2015)
Miscellaneous
Functional observational battery (FOB): Significant increases in some observational measures 
(male ICR mice) consistent with psychomotor stimulant properties (ranging between 3−10 mg/kg 
and 10−17 mg/kg): locomotion (first 10 min), exploration, circular ambulations, flattened body 
posture, hyperactivity, stereotyped head weaving, stereotyped head circling and stimulation. No 
significant increased noted for ataxia, retropulsion, bizarre behaviour and grooming.
Marusich, et al. (2014)
Intracranial self-stimulation (ICSS) thresholds: g Significant ICSS threshold reductions at 0.3 and 1 
mg/kg (~19 %) doses and comparable to methamphetamine. ED
50
: α-PVP = 0.35 mg/kg; 
methamphetamine = 0.2 mg/kg); at 5 mg/kg (or 3 mg/kg for methamphetamine) aversive effects 
observed and increase of ICSS thresholds.
Watterson et al. (2014)
Intravenous self-administration: h α-PVP considered similar to MDPV in potency and efficacy as 
a reinforcer; intake and lever discrimination of α-PVP higher than MDPV.
Aarde, et al. (2015)
Conditioned place preference (CPP): i
CPP was produced (0.3−10 mg/kg) with U-shaped dose−effect curve, i.e. no CPP at high (30 mg/
kg) and low doses (0.1 mg/kg).
Gatch, et al. (2015)
a  Balb/c male mice (8 weeks old) and comparison with saline. Locomotor activity measured for 120 min after administration using a video tracking 
system. Antagonism experiment: D
1
 receptor antagonist (+)-SCH23390 (50 μg/kg, i.p.), D
2
 receptor antagonist sulpiride (50 mg/kg, i.m.); antagonists 
administered 30 min before α-PVP (25 mg/kg) treatment. Locomotor activity measured for 60 min.
b  Locomotor activity studies: male ICR mice; monitoring horizontal movements (two 4-beam infrared arrays) / beam breaks for 60 min following α-PVP 
administration (1, 3 and 10 mg/kg, i.p.); D
1
 receptor antagonist (+)-SCH23390 (30 μg/kg, s.c.) given 30 min before drug administration; FOB studies: 
Male ICR mice.
c Male Wistar rats; activity rate determined by radiotelemetry for 180 min following α-PVP administration (1, 5.6 and 10 mg/kg, i.p.).
d  Male Swiss Webster mice in temperature environment of 22−24 °C; panel of 16 infrared beams; α-PVP doses 1, 2.5, 5, 10 and 25 mg/kg (i.p.); 
horizontal activity measured for 8 h.
e  Male Sprague-Dawley rats; α-PVP doses 0.1, 0.25, 0.5, 1, 2.5, 5 and 10 mg/kg (i.p.); rats trained to discriminate cocaine (10 mg/kg, i.p.) or methamphet-
amine (1 mg/kg i.p.) from vehicle (saline) using two-lever choice methodology.
f  Male Sprague-Dawley rats; trained to discriminate methamphetamine (1.0 mg/kg) from saline using fixed-ratio (FR) 20 schedule; α-PVP doses 
0.25–2.0 mg/kg (i.p.); cocaine (1.0–8.0 mg/kg) used as positive control.
g  Male Sprague-Dawley rats, unilaterally implanted stainless steel bipolar electrode into medial forebrain bundle; α-PVP in comparison with metham-
phetamine (both 0.1, 0.3, 1, and 3 mg/kg; i.p.); training: nose-poke responses on FR1 schedule.
h  Male Wistar rats; fixed-ratio 1 dose-response testing (1 h) (trained on 0.1 mg/kg/infusion) and progressive-ratio (3 h), dose-response testing 
(dose-response: 0.018–0.56 mg/kg/infusion).
i Male Swiss Webster mice; α-PVP place conditioning doses of 0.1, 0.3, 1, 3, 10, 30 mg/kg (i.p.).
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TABLE 8
Biotransformation data associated with α-PVP
Comments Reference
Rat urine: detected biotransformation products included PVP, N,N-bis-dealkyl-PVP, the pyrrolidin-
2-one derivative 2’’-oxo-PVP, hydroxyalkyl-PVP, hydroxyphenyl-N,N-bis-dealkyl-PVP, 
hydroxyphenyl-PVP, hydroxyalkyl-2’’-oxo-PVP, carboxy-4-oxo-PVP, hydroxy- phenyl-2’’-oxo-PVP, 
di-hydroxy-PVP, hydroxyphenyl-carboxy-4-oxo-PVP, and hydroxyphenyl-carboxy-4-oxo-PVP. Side 
chain hydroxylation of α-PVP catalyzed following exposure to human hepatic cytochrome-P450 
(CYP) enzymes CYP2B6, CYP2C19, CYP2D6, and CYP1A2, respectively. a
Sauer et al. (2009), Meyer & Maurer 
(2010)
Identification of seven Phase I metabolites in authentic human urine samples; transformation 
steps included as reduction, hydroxylation, hydroxylation + dehydrogenation, reduction + 
hydroxylation + dehydrogenation, degradation of pyrrolidine ring, hydroxylation + dehydrogenation 
+ ring opening + oxidation, and hydroxylation + oxidation, respectively. The reduced ketone, i.e. 
1-phenyl-2-(pyrrolidin-1-yl)pentan-1-ol (HO-α-PVP), was found to be the most abundant species 
in the analyzed human urine samples and in samples derived from in vitro experiments with 
human liver microsomes.
Tyrkkö et al. (2013)
Death: detection of α-PVP and HO-α-PVP in various biofluids and solid tissues. Hasegawa et al. (2014)
Detection of the hydroxyalkyl-PVP species was observed in samples obtained in casework and in 
vitro studies.
Friscia et al. (2015)
Urine samples obtained from a substance user following intravenous administration of a drug 
mixture; urinary elimination half-live was estimated as 22 h for α-PVP based on the first five days 
of urinary analysis. Elimination half-live of α-PVP estimated for the second half period 6-10 days 
after injection was 40 h.
Namera et al. (2014)
Authentic human urine samples revealed the detection of HO-α-PVP diastereomers, 2’’-oxo-α-
PVP, 2’’-HO-α-PVP and HO-α-PVP glucuronide.
Shima et al. (2014)
Large-scale investigation of submitted urine samples; detection of the unchanged molecule, 
metabolites derived from pyrrolidine degradation and primary amine formation followed by 
reduction to alcohols. The suggestion was made that direct reduction to HO-α-PVP without 
pyrrolidine degradation may be less pronounced in PVP-type substances.
Uralets et al. (2014)
In vitro Phase I and Phase II metabolism study; detection of six Phase I and two glucuronidated 
metabolites. Phase I metabolites were formed following reduction, hydroxylation, and pyrrolidine 
ring transformation. The main metabolite formed under the investigated conditions was the 
reduced β-hydroxy-2’’-oxo-PVP species that was associated predominantly with recombinant 
human CYP2C19, CYP2B6 and CYP2C9 activity as determined by separate in vitro studies.
Negreira et al. (2015)
Death: in addition to the detection of pentedrone, the presence of α-PVP and OH-α-PVP was 
noted in various biofluids and solid tissues.
Sykutera et al. (2015)
a Screening of rat urine (male Wistar, α-PVP administration by gastric intubation, 20 mg/kg and 1 mg/kg) following analysis by gas chromatography mass 
spectrometry and chemical derivatisation.
Pharmacokinetics
Detailed data on the metabolic transformation of α-PVP 
in humans is not available, however a number of in vitro 
studies have recently been published that provide 
some initial data. In addition, some information became 
available from casework samples related to acute 
intoxications and deaths (Table 8). From what has been 
reported so far it would appear that the parent 
molecule is frequently detectable in a variety of 
biofluids (see also Section C). Other metabolites that 
may be suitable for the implementation of targeted 
investigations include the reduced β-hydroxy (HO-PVP) 
species and a range of additional analytes associated 
with modifications at the pyrrolidine ring, phenyl ring 
and α-alkyl group.
Interactions with other drugs or medicines
No studies were identified that have examined the 
interaction of α-PVP with other substances, including 
medicinal products. Table 8 provides details of some of 
the enzymes that have been identified from animal 
studies and in vitro studies using recombinant human 
enzymes and that are thought to be involved in the 
metabolism of α-PVP.
| A3. Psychological and behavioural effects
No clinical studies were identified that have investigated 
the psychological and behavioural effects of α-PVP in 
humans. The limited information on the psychological 
and behavioural effects from self-reported user 
experiences is summarised in Section D.1.2.1; the 
limited information on the characteristics and behaviour 
of users is summarised in Section D3.3.
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Behavioural studies in animals are summarised in 
Section A2, Table 7.
| A4. Legitimate uses of the product
α-PVP and the corresponding enantiomers are used in 
scientific research as well as analytical reference 
materials in clinical and forensic case work/
investigations. There are currently no other indications 
that α-PVP may be used for other legitimate purposes.
There are no reported uses of α-PVP as a component in 
industrial, cosmetic or agricultural products. In addition, 
a search of the REACH registered substances database 
hosted by the European Chemicals Agency (ECHA) using 
the CAS Registry Numbers listed in Table 1 returned no 
results.
There is no marketing authorisation (existing, ongoing or 
suspended) for α-PVP neither in the European Union nor 
in the Member States that responded to the request for 
information from the European Medicines Agency which 
was undertaken as part of the Joint Report process 
(EMCDDA and Europol, 2015).
There is no information to suggest that α-PVP is currently 
used in the manufacture of a medicinal product in the 
European Union. However, in the absence of a European 
Union database on the synthetic routes of all medicinal 
products it is not possible to confirm whether or not 
α-PVP is currently used in the manufacture of 
a medicinal product.
I  Section B. Dependence  and abuse potential
| B1. Animal data
Section A2 provides a summary of data obtained from in 
vitro and in vivo animal studies. Data summarised in 
Table 6 and Table 7 indicates that the physiological and 
behavioural responses associated with α-PVP 
administration were consistent with those frequently 
reported with other psychomotor stimulants such as 
MDPV, cocaine, and methamphetamine. For example, 
α-PVP was shown to increase extracellular dopamine 
levels in dialysates collected from mice striatum using in 
vivo microdialysis, and dopamine transporter occupancy 
have been traced in rhesus monkeys using neuroimaging 
(Table 6). Consistent with the psychostimulants 
mentioned above, α-PVP was able to induce locomotor 
activity and conditioned place preference. More specific 
functional assays included drug discrimination and 
self-administration studies, which confirmed that α-PVP 
showed functional similarities displayed by MDPV, 
cocaine, and methamphetamine used as training drugs 
(Table 7).
Taken together, the available data appear to show 
sufficient predictive validity to consider abuse liability of 
α-PVP. These data are suggestive of a possible 
dependence potential in humans. However, further 
research is needed in order to obtain a more detailed 
understanding of the mode and mechanism of action of 
α-PVP (including its two enantiomers), in respect to its 
abuse liability and dependence potential, and how the 
data obtained from animal studies relate to humans.
| B2. Human data
No studies were identified that have investigated the 
dependence and/or abuse potential of α-PVP in humans.
Self-reported user experiences suggest that re-dosing 
occurs in some individuals (15).
I Section C. Prevalence of use
|  Information from seizures, collected and biological samples
The formal notification of α-PVP to the European Union 
Early Warning System (EU EWS) was in April 2011. This 
was related to a seizure of over 5 kg of white powder 
made by French Customs authorities at Charles de 
Gaulle Airport, Paris. The powder also contained 
pentedrone. Since then, the substance has been 
(15) Data from the online survey conducted by the I-Trend project which 
was completed by 1074 Polish citizens aged 16+, found that out of 36 
respondents who reported α-PVP as the last new psychoactive 
substance they had used, 16.7 % (n = 6) reported a ‘strong craving to 
use more’ α-PVP after the initial dose. Users on a Finnish discussion 
forum reported re-dosing after 30–120 minutes, since ‘the effects 
don’t last very long’, being sometimes as short-lived as 15 minutes ‘so 
one has to take a new dose shortly after the previous one’. Finally, one 
user in an Italian internet forum cautioned against re-dosing, 
suggesting that doing it 2 or 3 times in a short period of time brings 
about impulsive behaviour which results in continuous re-dosing (‘you 
can no longer stop’).
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detected in all 28 EU Member States, Turkey and Norway 
(16) (EMCDDA & Europol, 2015) (17).
Of note is that it appears that prior to the detection 
reported by France in 2011, α-PVP was also detected in 
Germany in 2005. No further details were available on 
this detection (Westphal et al., 2005).
Information from seizures
At the time of writing the Joint Report, 26 Member 
States (18), Norway and Turkey had reported seizures (19) 
of α-PVP to the EMCDDA. More than 5,200 seizures 
were reported in total, with eight countries reporting 
more than 100 seizures each: the United Kingdom 
(1094), Poland (938), Finland (787), Slovakia (502), 
Sweden (451), Ireland (336), Hungary (313) and Turkey 
(256).
α-PVP has typically been seized in powder form. Until 
July 2015, more than 750 kg of powdered substance 
have been seized in Europe. To a lesser extent, tablets 
(12,400 units), vegetable material containing α-PVP 
(<150 grams), liquids (< 150 ml), blotters (68 units), 
powder-filled capsules (3 seizures) and jelly gums (2 
units) have also been seized.
In around 35 % of these seizures, α-PVP was found in 
combination with other substances (Section D3.1).
Countries reporting larger seizures of α-PVP in powder 
form were, in decreasing order: Spain (312 kg), 
Netherlands (140), France (81), Ireland (63), United 
Kingdom (62), Hungary and Finland (24 each) and 
Poland (17). The biggest single powder seizure occurred 
in April 2015 in Spain, when the Spanish National 
Customs Surveillance Service seized almost 260 kg of 
(16) ‘Detections’ is an all-encompassing term and may include seizures 
and/or collected and/or biological samples that are analytically 
confirmed. Seizure means a substance available (seized) through law 
enforcement activities (police, customs, border guards, etc.). 
Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and 
research purposes. Biological samples are those from human body 
fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.) 
(17) Unless indicated otherwise, information provided in this section has 
been extracted from the EMCDDA–Europol Joint Report on α-PVP 
(EMCDDA–Europol, 2015). The data collection for the preparation of 
the Joint Report was finalised on 8 July 2015.
(18) Bulgaria and Romania did not report seizures. Note, however, that the 
Bulgarian and Romanian Europol National Units reported the 
detection of α-PVP to Europol.
(19) Many ‘seizures’ relate to individual case-level data, however, some 
data provided to the EMCDDA are aggregated at the country level. 
Some of the data from the United Kingdom are reported as ‘records’, 
where several records may come from the same case. Data is drawn 
from the Joint Report Questionnaires and data provided in the 
bi-annual data gathering (EU EWS progress and final reports) and 
from individual Reporting forms submitted on an ad hoc basis.
α-PVP in 13 containers at Barcelona Airport shipped 
from China. Single powder seizures over 10 kg were 
reported in seven Member States and single seizures of 
over 1000 tablets were reported in three Member States: 
Slovakia (7157 units), Hungary (3768) and Finland 
(1136).
After 8 July 2015, updated information on detections of 
α-PVP has been collected by the EMCDDA. Updated 
information on seizures, that was not included in the 
Joint Report, has been provided by eight countries and 
amounts to over 260 individual seizures and more than 
26 kg of the substance: United Kingdom (over 90 
seizures: 12.1 kg in powder form and tablet), Sweden (87 
seizures: 1.9 kg of powder, 25.5 ml of liquids and 2 
tablets), Poland (72 seizures amounting to 2.4 kg of 
powder, liquids and herbal material), Ireland (4 seizures 
amounting to 62 grams of powder), Norway (3 seizures 
of powder amounting to 6 grams), Spain, Slovakia and 
the Czech Republic (one seizure of powder each, of 7.2 
kg, 1.5 kg and 1 kg, respectively). In addition to Spain, 
Slovakia, and the Czech Republic, two countries 
reported single seizures over 1 kg: Poland (a seizure of 
1.3 kg) and the United Kingdom (1 kg).
Information on the production, processing and 
distribution of α-PVP in Europe has been reported to 
Europol. This relates to two illicit production sites were 
seized in Poland and two processing sites were 
dismantled in Hungary (tableting plants where 
pentedrone was also being processed). In terms of 
trafficking and distribution, it was found that in general 
bulk quantities of α-PVP are mainly imported into the EU 
from China and then further distributed from the 
Member States, rather than produced within Europe 
(Section F).
Information from collected samples
Eleven countries reported fifty samples collected from 
users or purchased on the Internet, which contained 
α-PVP (20) (Austria, Belgium, Czech Republic, Denmark, 
France, Hungary, the Netherlands, Slovenia, Spain, 
Turkey and the United Kingdom).
Three countries reported powders sold as MDMA: 
Austria and Spain (one case each) and the United 
Kingdom (7). In France, powders, capsules containing 
powder and pellets were sold either as 
methamphetamine, pentedrone and ethylphenidate or 
as branded ‘legal high’ products. In the United Kingdom 
a sample sold as ‘NRG-3’ was also reported. In Spain, 
(20) Countries are listed in alphabetical order.
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a powder containing α-PVP was sold as ketamine in one 
case and a yellow jelly was collected from a user in 
another case.
After 8 July 2015, updated information on detections of 
α-PVP in collected samples has been provided by the 
Czech Republic and Spain. In the Czech Republic, three 
samples of powder were collected from clients in a harm 
reduction programme; two of the samples also 
contained MDPBP and the third one contained 
methamphetamine. In Spain, a sample of powder sold as 
ecstasy was collected from a user in a recreational 
setting.
Information from biological samples
Nine Member States (Finland, France, Hungary, Ireland, 
Italy, Poland, Spain, Sweden and the United Kingdom) as 
well as Norway reported a total of more than 1800 
detections where α-PVP was analytically confirmed in 
biological samples. These included 306 serious adverse 
events (191 acute intoxication and 115 deaths). The 
remaining detections related to: patients undergoing 
drug treatment; persons suspected of driving under the 
influence of drugs; persons suspected of having 
consumed drugs, committed minor offenses or crimes; 
and, criminal justice drug screening programs.
| Availability, supply, price
According to searches conducted in English for ‘α-PVP’, 
a Wikipedia entry was created in September 2009‎ 
(Wikipedia, 2015). Self-reported user experiences 
appear to have been posted to user websites from 2011 
(Flashback, 2015; Drugs Forum, 2015) and 2012 
(Bluelight, 2015; Shroomery, 2015) onwards.
Data from seizures reported to the EMCDDA suggest 
that most of the bulk quantities of α-PVP in Europe are 
mainly imported from China. In addition, more than 50 
kg of α-PVP has been seized from two production sites 
in Poland where the drug was synthesised (Section F).
Online vendors may be an important supply channel for 
wholesale and retail amounts of α-PVP. Bricks-and-
mortar shops and street-level drug dealers have also 
supplied α-PVP.
α-PVP has been sold as a drug in its own right (including 
marketing as a ‘research chemical’), as well as in 
branded ‹legal high› products, and surreptitiously as 
other drugs. It appears that in the case of many of the 
‹legal high› products there is no indication on the 
marketing materials and product packaging that they 
contain α-PVP. These products include α-PVP in powder 
form, as tablets, and mixed with plant material. This 
includes ‘legal high’ products sold under the commonly 
used guises of ‘bath salts’, ‘plant food’, and ‘insect 
repellents’ in order to circumvent legislation (EMCDDA & 
Europol, 2015).
Availability from Internet vendors
A structured search of the surface web (21) conducted in 
English in July 2015 for Internet vendors (22) offering 
α-PVP identified 65 vendors that appeared to be based 
in, and/or claim to have presence in, the European Union 
(n=28 sites), United States (n=13 sites), China (n=32 
sites), India (n=3 sites), or Russia (n=6 sites). α-PVP was 
typically marketed on these sites as a ‘research 
chemical’ (EMCDDA and Europol, 2015).
17 of the sites only provided quantities and prices for 
α-PVP on application. 11 of the sites listed prices but did 
not specify quantities. The remaining 37 sites listed 
quantities and prices. Prices were listed in EUR on 14 
sites, in USD on 22 sites, and in GBP on 1 site (23). The 
minimum quantity offered was 1 g (n=16 sites) with 
a mean price of EUR 17.50 (EUR 12–24). The maximum 
quantity offered was 10 kg (n=4 sites) with a mean price 
of EUR 17000. Most of the 37 sites offered quantities 
ranging from 1 g (n=16 sites) to 1 kg (n=21 sites). The 
mean price for 1 g was EUR 17.50. The mean price for 10 
g (n=26 sites) was EUR 134.50 (EUR 63–180) (EUR 
13.45/g). The mean price for 100 g (n=33 sites) was EUR 
594.5 (EUR 270–1200) (EUR 5.94/g). The mean price for 
1 kg (n=30 sites) was EUR 2490 (EUR 1260–3600) 
(EUR 2.49/g). The mean price for 5 kg (n=9 sites) was 
EUR 10500 (EUR 4545–12000) (EUR 2.10/g). The mean 
price for 10 kg (n=4 sites) was EUR 17000 (EUR 6705–
23000) (EUR 1.70/g).
(21) The search of online vendors of α-PVP was performed on google.co.uk 
using three search strings: ‘buy a-PVP’, ‘buy alpha-PVP’ and ‘buy 
pyrrolidinopentiophenone’. For each of the search strings the first 100 
results were recorded and the sites reviewed. The results of the three 
searches partially overlapped; duplicate sites were removed from the 
analysis. Information on physical location of the vendor, quantities and 
prices, and substance marketing was then recorded for each vendor 
URL.
(22) This includes vendors that appear to be consumer-orientated as well 
as vendors, for example on B2B sites, which appear to be 
manufacturers and/or wholesalers. It excludes those selling α-PVP 
through online classified advertisements, social media, and user 
websites.
(23) Prices listed in USD were converted to EUR according to Google 
exchange rate from the 27.07.2015 (USD 1 = EUR 0.90). Prices listed 
in GBP were converted to EUR according to Google exchange rate 
from the 28.07.2015 (GBP 1 = EUR 1.41).
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In addition to the structured search of the surface web, 
data reported to the EMCDDA noted that:
 § In 3 out of the 4 acute intoxications reported to the 
EMCDDA where the source of the substance was 
known, α-PVP had been obtained online; in the 
remaining case, the source was reported as ‘internet 
and drug dealer’.
 § Data on collected samples reported by France, found 
that most the products containing α-PVP were 
originally sourced from the Internet directly by the 
user or indirectly through a dealer or a friend. 
Reported prices per capsule were 15 and 20 EUR and 
between 20 and 80 EUR per gram of powder.
Sale as other drugs
Data from seizures, collected samples, and acute 
intoxications reported to the EMCDDA as well as data 
from Sundström et al., (2015) suggest that α-PVP is sold 
surreptitiously as other psychoactive substances, 
including controlled drugs. These include: MDPV 
(Sweden and Finland), methamphetamine (France and 
Ireland), ecstasy (24), pentedrone (France), 
ethylphenidate (France), MDMA (Austria, Spain, and the 
United Kingdom), ketamine (Spain) and cocaine (United 
Kingdom and Ireland).
| Prevalence of use
No studies were identified that have investigated the 
prevalence of use of α-PVP in the general population.
Along with the data on biological samples (see above), 
data on the prevalence of use of α-PVP appears to be 
limited to the following studies:
 § an Internet-based survey of Polish citizens aged 16 
and over, conducted by the I-Trend project during 
2014;
 § a study of fatal poisonings in people who use drugs in 
the Nordic countries based on 2012 data (Simonsen 
et al., 2015);
 § a study of patterns of drug abuse among drug users 
attending two different drug treatment centres in 
Finland, conducted in 2013 and 2014 (Sundström et 
al., 2015); and,
 § data provided by Ireland in respect to clients 
attending a methadone maintenance program.
(24) Reports of seizures of tablets with markings such as ‘Lacoste’, 
‘Playboy’, ‘STADA1’ and ‘Homer Simpson’.
Poland reported that the I-Trend project undertook an 
Internet survey of Polish citizens 16+, who were 
recruited mainly through adverts on Facebook during 
2014. Respondents (n=1,385) appeared, on the whole, 
to be relatively experienced drug users (25), mostly young 
people (mean 21 years old, median 19, mode 17) and 
male (68.5 %). The lifetime prevalence for α-PVP in this 
population was 10.0 % (138 users, n=1,385). α-PVP was 
the last new psychoactive substance to be used by 3.4 % 
(n=36) of the respondents (n=1074). Of these, 38.9 % 
(n=14) had taken it at least 20 times in the previous year.
Simonsen et al., (2015) reported that in Finland in 2012, 
α-PVP was detected in 4.9 % of deaths (n=8/162) of 
individuals ‘who according to information from the police 
and/or autopsy report [were] known to have abused 
drugs intravenously and/or abused drugs’. In Sweden, 
α-PVP was detected in 0.4 % of deaths (n=1/255).
Sundström et al., (2015) studied patterns of drug use 
among two groups who either:
a) irregularly attended a harm reduction unit providing 
social and healthcare counselling to individuals 
using intravenous drug (n=32); or,
b) regularly attended a rehabilitation clinic, such as 
patients undergoing opioid maintenance therapy or 
drug withdrawal therapy (n=36).
α-PVP was the most frequently detected new 
psychoactive substance in biological samples in clients 
attending the harm reduction unit (38 % of all analytical 
findings, n=34 urine samples) than for those who 
regularly attended a rehabilitation clinic (1 % of all 
analytical findings, n=67 urine samples). The authors 
suggest that while 10 of the users from the harm 
reduction unit self-reported using MDPV, data from 
urinalysis suggests that they were actually using α-PVP. 
The authors suggest that this is an indication that α-PVP 
has been replacing MDPV in the market in Finland.
Ireland reported that between 2011 and the end of June 
2015 there had been 112 urine samples mainly provided 
by patients in a methadone maintenance program where 
α-PVP was detected (26). Testing for new psychoactive 
substances was performed on request where use of 
these substances was suspected; some patients 
provided multiple samples (Table 9).
(25) For example, life time prevalence was: 97.8 % for alcohol; 94.9 % for 
tobacco; 93.1 % for cannabis, 57.1 % for amphetamine/
methamphetamine, 42.5 % for new psychoactive substances, 32.4 % 
for ecstasy pill or MDMA powder, 25.9 % for LSD or psilocybin 
mushrooms, 20.9 % for cocaine, etc.
(26) See also McNamara et al., (2015) for further details.
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TABLE 9
Number of urine samples where α-PVP was detected 
that were mainly provided by patients in a methadone 
maintenance program in Ireland
Year
Total number 
of urine 
samples tested
Number of urine samples 
where α-PVP was 
detected (% of total)
2011 151 11 (7.3 %)
2012 412 21 (5.1 %)
2013 486 18 (3.7 %)
2014 418 33 (7.9 %)
2015 (Jan–June) 371 29 (7.8 %)
Overall, the available data suggest that α-PVP is being 
used by recreational stimulant users as well as high risk 
drug users. In the latter case this includes people who 
inject opioids and stimulants, some of whom are 
accessing low-threshold harm reduction services and/or 
receiving opioid substitution treatment. The extent of the 
possible appeal of α-PVP to these groups of users in 
general is unknown.
I Section D. Health risks
| D1. Acute health effects
D1.1. Animal data
The median lethal dose (LD
50
) of α-PVP hydrochloride 
administered by intravenous injection to mice is 38.5 
mg/kg (Seeger, 1964). While LD
50 
data on other relevant 
substances is not available in the report by Seeger 
(1964), data from other studies have reported the 
following:
 § an LD
50 
of 43 mg/kg for pyrovalerone when 
administered by intravenous injection to mice 
(Usdin & Efron, 1972);
 § an LD
50
 of 12.5 mg/kg for amphetamine when 
administered by intravenous injection to mice 
(Haas & Forth, 1956);
 § an LD
50
 of 75 mg/kg for cocaine when administered 
by intraperitoneal injection to mice (Hayase et al., 
1996); and,
 § an LD
50
 97 mg/kg for MDMA when administered by 
intraperitoneal injection to mice (Davis et al., 1987).
No other studies were identified that investigated the 
acute health effects of α-PVP and/or its metabolites in 
animals.
Data from an in vitro cytotoxicity bioassay (ToxiLightTM 
bioassay kit) found that α-PVP (100 μM, 4 h of 
incubation at 37°C) did not cause cytolysis under the 
conditions studied (Rickli, et al., 2015).
D1.2. Human data
No clinical studies were identified that have examined 
the acute health effects of α-PVP and/or its metabolites 
in humans.
D1.2.1. User reports
Data reported by the Member States (27) and identified 
from open source information (e.g. Simonsen, et al. 
(2015) and Sundström et al. (2015)) suggests that 
α-PVP is used by recreational stimulant users and high 
risk drug users, including those who inject opioids and 
stimulants.
In respect to psychological and behavioural effects, data 
from the online survey conducted by the I-Trend project 
which was completed by 1 074 Polish citizens aged 16+, 
found that out of 36 respondents who reported α-PVP as 
the last new psychoactive substance they had used: 
(multiple responses allowed):
 § 38.9 % (n=14) experienced aggression;
 § 36.1 % (n=13) experienced fatigue, exhaustion, 
sleepiness;
 § 33.3 % (n=12) experienced seizures;
 § 30.6 % (n=11) experienced shaking;
 § 30.6 % (n=11) experienced depression, dejection;
 § 30.6 % (n=11) experienced strong paranoia, fear, 
anxiety;
 § 19.4 % (n=7) experienced muscle aches, cramps, jaw 
clenching;
 § 16.7 % (n=6) experienced strong craving to use more;
 § 11.1 % (n=4) experienced extreme agitation and 
excitement, sleeplessness;
Users in a Finnish discussion forum report re-dosing 
after 30–120 minutes, since ‘the effects don’t last very 
(27) This includes data from: serious adverse events reported to the 
EMCDDA; questionnaire responses from 6 users providing information 
to drug testing organisation (SINTES, France); an online survey 
completed by 1385 people in Poland (I-Trend); reports from 
representatives of the Finnish Drug Users Union (FDUU); and, 
monitoring of self-reported user experiences posted on user websites. 
In the latter respect this included data from: France, which was 
obtained from systematic monitoring of 3 forums (902 discussions 
threads, 4 of which specifically related to i-PVP) and from a special 
project in French and English speaking forums (8 forums, 2 discussion 
threads on α-PVP); Finland, where 2 online discussion forums were 
monitored (www.paihdelinkki.fi and http://psyvault.net); and, in Italy 
where 2 cases were reported from discussion threads (in Italian) on 
www.psychonaut.com 
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long’, being sometimes as short-lived as 15 minutes ‘so 
one has to take a new dose shortly after the previous 
one’. A user in an Italian internet forum cautioned against 
re-dosing, suggesting that doing it 2 or 3 times in a short 
period of time brings about impulsive behaviour which 
results in continuous re-dosing (‘you can no longer stop’).
Self-reported user experiences provided in the ‘Erowid 
Experience Vaults’ suggest that users may experience 
a range of adverse effects (Erowid, 2015).
D.1.2.2. α-PVP associated acute toxicity
Acute intoxications reported by the Member States
205 acute intoxications associated with α-PVP were 
reported by 8 Member States: France (10 cases), 
Germany (2), Ireland (5), Italy (1), Poland (2), Slovakia (1), 
Spain (2), and Sweden (182) (28). These typically related 
to acute presentations at hospital emergency 
departments. The acute intoxications occurred between 
2011 and 2015.
Case-level data was provided for 43 of these cases: 
France (10 cases), Germany (2), Ireland (5), Italy (1), 
Poland (2), Slovakia (1), Spain (2), and Sweden (20). In 
order to minimise the potential for confounding caused 
by other psychoactive substances, case-level data from 
Sweden was limited to 20 of the 182 reported cases 
where either α-PVP was the only substance that was 
analytically confirmed or where α-PVP was analytically 
confirmed along with ethanol and/or benzodiazepines 
and metabolites of benzodiazepines.
35 of the 43 cases were classified as non-fatal 
intoxications; in the remaining 8 cases the outcome of 
the intoxication was unknown: Germany (1 case), Poland 
(1), and Sweden (6).
In 29 of the 43 cases, α-PVP was analytically confirmed 
in one or more biological samples taken from the patient 
at or around the time of intoxication: France (4 cases), 
(28) The United Kingdom reported that the National Poisons Information 
Service (NPIS), which provide information on the number of accesses 
to information held on its online poisons information database 
TOXBASE® and details of telephone enquiries made to the service by 
health professionals, reported that in the financial year 2014 through 
to March 2015, NPIS did not receive any telephone enquiries relating 
to α-PVP or the common names ‘Flakka’ or ‘Gravel’. There were 2 
accesses to the α-PVP page on TOXBASE® during that year. For the 
period 1 April to 30 September 2015, three accesses to the α-PVP 
page were noted and one telephone enquiry concerning a case of 
recreational use of ‘gravel’ (a name sometimes associated with 
α-PVP) was recorded. No other enquiries were found using the search 
terms ‘alpha-PVP’ OR ‘alpha PVP’ OR ‘alphaPVP’ OR 
‘pyrrolidinovalerophenone’ OR ‘pyrrolidinopentiophenone’ OR 
‘O-2387’ OR ‘O2387’ OR ‘0-2387’ OR ‘02387’ OR ‘Flakka’. 
Italy (1), Poland (2), Spain (2), and Sweden (20). In the 
remaining 14 cases, α-PVP was not analytically 
confirmed: France (6 cases), Germany (2), Ireland (5), 
and, Slovakia (1); these latter cases have been excluded 
from the analysis below.
Thus of the 29 analytically confirmed cases, 23 related 
to non-fatal intoxications and 6 related to cases where 
the outcome is unknown.
Demographics
Of the 29 analytically confirmed acute intoxications, 24 
were male and 4 were female; data on sex was missing 
for one case. The mean age of the male cases was 33.9 
years (n = 21; median 32 years); data on age was missing 
for four male cases. The mean age of the female cases 
was 24.3 years (n = 4; median 24.5 years).
Substances analytically identified in biological samples
In 14 of the 29 analytically confirmed acute intoxications 
α-PVP was the only substance that was detected. In 5 
cases, α-PVP and ethanol were the only substances 
detected; in 2 cases α-PVP, benzodiazepines and 
metabolites of benzodiazepines were the only 
substances detected; in 4 cases it is not known or not 
reported if α-PVP was the only substance detected; in 1 
case α-PVP, ethanol, benzodiazepines and metabolites 
of benzodiazepines were the only substances detected; 
in 1 case α-PVP, pentedrone, and ethanol were the only 
substances detected; in 2 cases α-PVP and THC were 
the only substances detected.
Seriousness of the intoxications
Data on the seriousness of the intoxication were 
reported for 26 of the 29 analytically confirmed acute 
intoxications:
 § in 10 cases the seriousness of the intoxication was 
classified as life threatening, requiring treatment in 
hospital. Of these cases: in 5 cases α-PVP was the 
only substance that was identified; in 2 cases α-PVP 
and benzodiazepines and metabolites of 
benzodiazepines were the only substances identified; 
in 1 case α-PVP, ethanol, benzodiazepines and 
metabolites of benzodiazepines were the only 
substances identified; in 2 cases it was not known if 
other substances were identified;
 § in 15 cases the intoxication was classified as non-life 
threatening; and,
 § in 1 case the intoxication was classified as involving 
persistent or significant disability or incapacity. No 
further details were reported.
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Clinical features
Data on clinical features (29) were reported for 27 of the 
29 analytically confirmed acute intoxications. These 
were generally consistent with sympathomimetic 
toxicity. They included: tachycardia (17 cases); mydriasis 
(8); agitation (7) or anxiety (3); tremor (5) or 
fasciculation (1) or tetany (1); hyperthermia (6); 
hallucinations (6); hypertension (4); diaphoresis (4); 
restlessness (3); chest pain (2); convulsions (3) or 
seizures (2); reduced consciousness (2); somnolence 
(4); numbness (2); distorted perception (1) or temporal/
spatial disorientation (2); rhabdomyolysis (2); delirium 
(1); aggression (1); cardiac arrhythmia (1); hypotension 
(1), low oxygen saturation (1), impaired liver function (1); 
impaired coagulation (1); difficulty in talking (1); paranoia 
(1); hyperventilation (1); hypoventilation (1); respiratory 
distress (1); muscular symptoms (1); and, malaise (1).
In one case excited delirium was reported.
Route of administration
Data on the route of administration was available for 15 
of the 29 analytically confirmed acute intoxications.
 § in 6 cases the route of administration was reported as 
snorting (nasal insufflation);
 § in 5 cases the route of administration was reported as 
injection. In 1 of these cases it was reported that the 
(29) Including abnormal laboratory findings. 
substance was injected intravenously. The specific 
route of injection for the other 4 cases is not known;
 § in 3 cases the route of administration was reported as 
oral administration;
 § in 1 case the route of administration were reported as 
oral administration and injection; the specific route of 
injection was not reported.
Name of the substance/product used
Data on the name of the substance/product used was 
available for 23 of the 29 analytically confirmed acute 
intoxications. These were: ‘MDPV’ (9 cases), ‘alpha-PHP’ 
(3), ‘NRG3’ or ‘energy 3’ (2), ‘flakka’ (2), ‘crystal(s)’ (2), 
‘penta’ or ‘pentadrone’ (1), ‘APP’ (1), ‘3-MEC’ (1), ‘PV8’ 
(1), ‘internet drug’ (1).
Acute intoxications identified from open source 
information
Examples of case reports of acute intoxications 
published in the scientific literature that involved the 
detection of α-PVP are shown in Table 10. In cases 
where details were available, some of the clinical 
features described were consistent with 
sympathomimetic toxicity. However, the data also show 
that α-PVP was not always the only detected substance, 
which adds challenges in the attempt to identify causal 
relationships in all cases.
TABLE 10
Analytically confirmed acute intoxications associated with α-PVP that were identified from open source information
Year of 
publication
No. of 
cases
Sex,
age
Comments Reference
2013 1 M, 27 Admission to emergency department following nasal insufflation: 
heart rate was 128 beats/min, blood pressure 160/90 mmHg, 
respiratory rate 30 breaths/min, oxygen saturation 97 % and 
temperature 37.1°C, bilateral mydriasis; relevant initial laboratory 
data indicated rhabdomyolysis without renal failure: creatine 
kinase 1841 IU/L, myoglobin 275 μg/L, C-reactive protein 33.5 
mg/L and normal lactic acid. Hepatic and pancreatic parameters 
normal; patient confirmed occasional consumption of ‘NRG-3’ (a 
few days every 2 months for 6 months) by nasal route, also 
cannabis and alcohol. Twelve hours after last ‘NRG-3’ intake (10 
h after emergency admission), visual hallucinations were 
mentioned. Diazepam (20 mg, i.v.) and olanzapine (20 mg, i.v.) 
given to treat persistent anxiety, agitation, temporo-spatial 
disorientation and distorted perceptions. Urine positive for 
cannabis.
Purchase of product ‘NRG-3’ on Internet; α-PVP plasma 235 ng/
mL; urine > 5 μg/mL; THC positive
This case report is included in the data reported to the EMCDDA 
by France (see above).
Eiden, et al. (2013)
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Year of 
publication
No. of 
cases
Sex,
age
Comments Reference
2013 4 NRa The clinical features of the four cases were not reported; 
analytical method applied to analysis of hair.
Case 1: hair collected one month after most recent use; drug was 
injected several times with the aim to commit suicide. α-PVP (9.4 
ng/mg) and α-PBP (3.1 ng/mg) detected 10-30 mm from scalp 
(2nd segment); 7.5 and 3.1 ng/mg in 3rd segment.
Case 2: patient was arrested and hospitalized; α-PVP detected 
10-30 mm and 40-90 mm from scalp, e.g. 40+ ng/mg and ~50 
ng/mg in segments 2 and 3.
Case 3: Concentrations of α-PVP, α-PBP and MDPV decreased in 
hair segments > 20mm from the scalp; hair was dyed brown 
20-30 mm from scalp; significant differences noted in MDPV and 
α-PVP concentrations between bleached and unbleached hair 
segments. α-PVP (320+ ng/mg), MDPV (300+ ng/mg) detected 
in first segment; α-PVP, α-PBP and MDPV detected in segment 2.
Case 4: Patient consulted hospital. α-PVP detected (4.5+ ng/mg) 
in pubic hair in segments 2 and 3 (20-40 mm from skin).
Namera, et al. 
(2013a)
2014 1 M, 46 Admission to emergency department (in 2013) following 
ingestion of zolpidem with suicidal intent; no recorded history of 
psychiatric disorders but active chronic hepatitis C and Gilbert’s 
syndrome. Patient’s condition diagnosed as persistent 
substance-induced psychosis, secondary to prolonged intake of 
MDPV, mephedrone, butylone and α-PVP. Continuous use (from 
one to three times a week) of a non-specified recreational drug 
since July 2012 was mentioned. Powdered material analysed to 
confirm the four substances. Haloperidol decanoate (150 mg) 
administered every 4 weeks. Slight improvement noted about 
persecutory delusion but no change in insight. Traces of MDPV 
were detected in urine.
Dragogna et al. 
(2014)
2014 1 M, 34 Impaired driving and evaluation by drug recognition expert. Poor 
navigation observed; driver appeared confused, disoriented and 
agitated at times; involuntary muscle movements at various 
times; dilated pupils, elevated systolic blood pressure (150/82 
mmHg). Blood analysis: α-PVP (63 ng/mL) and methylone (6.1 
ng/mL); positive for ethylone.
Knoy, et al. (2014)
2014 1 M, ‘in his 40s’ No clinical features reported. Several intravenous injections of 
‘unregulated drug’ with intention to commit suicide and 
admission to hospital several hours afterwards. Urine was 
collected for analysis each morning for one month. Based on first 
five days of urinary analysis (below level of detection on day 10): 
urinary elimination half-lives 22 h and 11 h for α-PVP and α-PBP; 
elimination half-lives during second half period (6-10 days after 
injection) were 40 h and 30 h for α-PVP and α-PBP.
Detection of α-PVP and α-PBP, plus their pyrrolidin-2-one-type 
metabolites. Highest concentration in first sample > 32 h after 
final injection: α-PVP 1.2 and α-PBP 1.6 μg/mL.
Namera, et al. (2014)
2014 19 NRa No details reported. Urine samples collected at autopsy or 
represented clinical toxicology cases.
Shima, et al. (2014)
2014 8 NRa No details reported. Urine samples collected at autopsy or 
represented clinical toxicology cases. α-PVP urine levels 0.08–13 
mg/L but other substances (not specified) were also detected.
Tyrkkö, et al. (2013)
a NR: not reported.
D1.2.3. MT-45 associated deaths
Deaths reported by the Member States
Case-level data for 116 deaths associated with the use 
of α-PVP were reported by 8 Member States: Finland (37 
cases), France (2), Hungary (19), Ireland (5), Poland (26), 
Spain (1), Sweden (16) and the United Kingdom (10). 
These deaths occurred between 2012 and 2015.
In 115 cases, α-PVP was analytically confirmed in one or 
more biological samples taken from the decedents. In 
the remaining case α-PVP was not analytically 
confirmed, and this case has been excluded from the 
analysis below.
Demographics
Of the 115 deaths, 92 (80 %) were male and 23 (20 %) 
were female. The mean age of the male decedents was 
35.6 years (n = 72; median 32 years); the mean age of 
the female decedents was 35.3 years (n = 22; median 
34.5 years).
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Number of deaths by year
18 deaths occurred in 2012; 24 occurred in 2013; 49 in 
2014; and, 23 in 2015. The year of death was not known 
for 1 case.
Cause of death reported by the Member States
A review of the cause of death reported for the 115 
deaths found that:
 § In 23 (20 %) cases, α-PVP was reported as the cause 
of death or was reported as a contributing factor (i.e. 
α-PVP was explicitly mentioned). This includes 5 
cases where α-PVP was the only substance detected.
 § In the remaining cases there was alternative cause of 
death recorded or the cause of death was not known 
at the time of reporting. Where an alternative cause of 
death was reported, the manners of death were varied 
and included: hanging, drowning, fall, road traffic 
accident, carbon monoxide, blood loss, as well as 
cited drug intoxication.
Toxicological significance of α-PVP
In an attempt to evaluate the toxicological significance 
of α-PVP in the deaths reported, an assessment of the 
following evidence was considered in each case: 
presence and concentration (and pharmacological 
nature) of α-PVP; presence and concentration (and 
pharmacological nature) of other drugs present 
(including alcohol); circumstances of death; pathological 
findings at post-mortem, and cited cause of death. This 
allowed categorisation of the significance of α-PVP in 
the deaths as being of low significance (i.e. alternative 
cause of death), medium significance (i.e. α-PVP may 
have contributed to toxicity/death but other drugs 
present may have been more toxicologically significant) 
or high significance (i.e. α-PVP was cited as the cause of 
death or was assessed to have been likely to contribute 
to toxicity/death even in the presence of other drugs). In 
order to highlight potential interactions or contributing 
toxicology, the other substances found in the cases were 
characterised.
The results of this assessment concluded that in 21 
deaths α-PVP was either the cause of death or is likely to 
have contributed to death even in the presence of other 
substances; in 7 of these deaths α-PVP was the sole 
drug present. In 55 deaths α-PVP may have contributed 
to toxicity but other substances were present that may 
have been more toxicologically significant. In 39 deaths 
α-PVP was assessed to be of low significance, including 
an alternative cause of death. In the cases where other 
drugs were detected in addition to α-PVP (the majority) 
a wide variety of drugs were detected (including 
benzodiazepines, alcohol, opiates, opioids, 
antidepressants and anticonvulsants). Of other 
stimulants detected these included amphetamines, 
pseudoephedrine and synthetic cathinones (e.g. MDPV, 
pentedrone, 4-MEC, 3-MMC). Synthetic cannabinoids 
were also detected in some cases.
In the deaths where α-PVP was quantified, 
concentrations ranging from 0.003 mg/L to 2 mg/L in 
blood have been found. In cases where α-PVP would be 
regarded as being of low significance, the median blood 
concentration was 0.07 mg/L (range 0.003–1.38 mg/L), 
where α-PVP was of medium significance the median 
blood concentration was 0.09 mg/L (range 0.006–0.65 
mg/L) and in those cases where α-PVP was of high 
significance the median blood concentration was 0.47 
mg/L (range 0.02–2 mg/L).
In all deaths there was a lack of information regarding 
any symptoms experienced by the deceased prior to 
death, largely due to the manner of death (e.g. ‘found 
dead’ was the only information reported). However, in 
those instances where symptoms have been described, 
confusion, agitation, aggression, bizarre behaviour, 
seizures, high body temperature, rhabdomyolysis, 
sweating and increased heart rate were reported. 
Although other drugs were associated with most of 
these cases, the symptoms are consistent with those 
seen in acute intoxications.
Deaths identified from open source information
31 deaths that involved the detection of α-PVP in one or 
more biological samples were identified from the 
scientific literature. These cases were published 
between 2013 and 2015 and were from Japan 
(Hasegawa, et al., 2014), (Minakata, et al., 2014), (Nagai 
et al., 2014), (Namera, et al., 2013b), (Saito, et al., 2013), 
United States of America (Marinetti and Antonides, 
2013), (Richards-Waugh et al., 2013), (Shanks, et al., 
2013), Poland (Sykutera, et al., 2015) and Australia 
(Sellors et al., 2014), (Yap and Drummer, 2015). The 
manners of death, any symptoms and prevalence of 
other drugs were similar to those cases reported by 
Member States (above). Two of the case reports were 
also reported to the EMCDDA by France and Poland 
(Eiden, et al., 2013; Sykutera, et al., 2015).
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| D2. Chronic health effects
D2.1. Animal data
No studies were identified that have investigated the 
chronic health effects of α-PVP in animals.
D2.2. Human data
No studies were identified that have investigated the 
chronic health effects of α-PVP in humans.
| D3. Factors affecting public health risks
D3.1. Availability and quality of the new 
psychoactive substance on the market
Data from seizures reported to the EMCDDA suggest 
that, in general, bulk quantities of α-PVP in powder form 
are mainly imported into the EU from China. In this 
respect, it is important to note that on 1 October 2015 
the People’s Republic of China controlled α-PVP under 
national drug control legislation.
In addition to importation, two illicit production sites 
synthesising α-PVP have been seized in Poland. The 
α-PVP was intended for the domestic market and export 
(Section F).
α-PVP is offered for sale in small, retail quantities 
(1 gram upwards) and in bulk (kilogram) quantities by 
Internet retailers as a drug in its own right (Section C). 
The purity of these products may be claimed to be high 
but this has not been tested by forensic analysis.
Detailed information in respect to route-specific by-
products produced during the synthesis of α-PVP is 
currently not available. In addition, there are no 
quantitative data currently available on the impurities 
detected in seized and collected samples.
Information on purity was only available for 17 seizures 
reported to the EMCDDA. Here the purity ranged from 
23 % (2 seizures) to over 95 % (8 seizures) (Section A1.1).
α-PVP is also sold surreptitiously as other psychoactive 
substances, including controlled drugs such as MDPV and 
methamphetamine, as well as ‘ecstasy’ (30) (Section C).
(30) Seized street tablets found to contain α-PVP showed a range of 
markings and logos thus, raising the possibility that they may be sold 
as ‘ecstasy’ tablets on the illicit drug market.
Seizure data and collected samples reported by the 
Member States suggests that products found to contain 
α-PVP also contained other types of psychoactive 
substances: in around 35 % of the detections, α-PVP 
was found in combination with other substances 
including other cathinones (mainly MEC (31), MMC (32), 
pentedrone, MDPBP (33), ethylcathinone and MDPV), 
synthetic cannabinoids, and a range of other new 
psychoactive substances (such as MPA (34), 5-MeO-
MIPT (35), AMT (36) and 2-DPMP (37)), substances that 
are internationally controlled and/or controlled at 
EU-level (ketamine, PMMA (38), methoxetamine, MDMA, 
cocaine, amphetamine and heroin), benzodiazepines 
(etizolam, flubromazolam), and substances typically 
used as cutting agents and/or diluents such as 
benzocaine, lidocaine and caffeine.
Overall, the data suggests that while some individuals 
may be exposed to α-PVP intentionally, others may be 
exposed unintentionally after consuming a product 
(including ‘legal high’ products) with no indication that it 
contains α-PVP or following its ingestion as 
a component of a mixture of other active substances.
D3.2. Availability of the information, degree of 
knowledge and perceptions amongst users 
concerning the psychoactive substance and its 
effects
There is limited information on commonly used English-
language user websites regarding the effects and 
potential health/adverse effects related to the use of 
α-PVP (Section D1.2.1). The users and forum discussion 
participants appear to be generally aware of the 
psychostimulant-like effects of α-PVP. This includes 
awareness of both desired and undesired effects.
Data from the online survey conducted by the I-Trend 
project which was completed by 1074 Polish citizens 
aged 16+, found that out of 36 respondents who 
reported α-PVP as the last new psychoactive substance 
they had used: (multiple responses allowed):
 § 63.9 % (n=23) used it to bond with others/to socialise;
 § 58.3 % (n=21) used it to get high;
 § 44.4 % (n=16) used it to modify perception;
 § 44.4 % (n=16) used it to relax;
(31) Methylethcathinone (isomer not specified).
(32) Methylmethcathinone (isomer not specified).
(33) 3’,4’-Methylenedioxy-α-pyrrolidinobutyrophenone.
(34) Methylthienylpropamine.
(35) 5-Methoxy-N-methyl-N-isopropyltryptamine.
(36) α-methyltryptamine.
(37) 2-(Diphenylmethyl)piperidine.
(38) para-Methoxymethamphetamine.
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 § 27.8 % (n=10) used it to fight tiredness;
 § 25 % (n=9) used it provide themselves with energy 
(not sex related);
 § 19.4 % (n=7) used it to allay or alleviate anxiety;
 § 19.4 % (n=7) used it to stimulate brain activity for 
learning or work;
 § 16.7 % (n=6) used it to reduce the negative effects of 
another drug;
 § 8.3 % (n=3) used it to improve sexual intercourse;
 § 8.3 % (n=3) used it for other reasons;
 § 5.6 % (n=2) used it to sooth pain;
 § 2.8 % (n=1) used it to increase the positive effects of 
another drug;
 § 2.8 % (n=1) used it to flight sleeplessness.
Other effects reported on user websites include 
‘euphoria’ and ‘increased libido’ (Finland, France).
D3.3. Characteristics and behaviour of users 
(including risk factors, vulnerability, etc.)
Information on the characteristics and behaviour of 
users of α-PVP is limited.
The available data suggests that α-PVP is used by 
recreational stimulant users and high-risk drug users 
(Section C). In the latter case this includes people who 
inject opioids and stimulants, some of whom are 
attending low threshold harm reduction services and 
drug treatment services, including opioid substitution 
treatment services. The available data also suggests that 
polydrug use might be common in those using α-PVP.
Data from the online survey conducted by the I-Trend 
project which was completed by 1074 Polish citizens 
aged 16+, found that out of 36 respondents who 
reported α-PVP as the last new psychoactive substance 
they had used:
 § 38.9 % (n=14) had used α-PVP on 20 days or more in 
the last 12 months;
 § 11.1 % (n=4) had used α-PVP on between 10 and 19 
days in the last 12 months;
 § 16.7 % (n=6) had used α-PVP on between 4 and 9 
days in the last 12 months;
 § 19.5 % (n=7) had used α-PVP on between 1 and 3 
days in the last 12 months;
 § 13.9 % (n=5) had not used α-PVP at all in the last 12 
months.
A case-control study conducted in Dublin, Ireland, 
following an outbreak of recently acquired HIV infections 
among homeless people who inject drugs found that the 
injection of ‘snow blow’—which the authors suggest is 
α-PVP—was strongly associated with HIV infection 
(adjusted odds ratio: 49; p=0.003) (Giese et al., 2015). It 
is important to note that the epidemiological link 
between ‘snowblow’ and α-PVP suggested by the 
authors is limited to the analytical detection of α-PVP in 
the urine of 5 of 12 HIV positive cases and the detection 
of α-PVP in the urine of patients some of whom are in 
opioid substitution treatment programs (See Section 
C and McNamara et al., 2015). Data are not provided on 
when the urine samples of the cases were taken. No 
urinalyses appear to have been conducted on controls. 
An unequivocal epidemiological link between ‘snowblow’ 
and α-PVP was not reported in the study.
D3.4. Nature and extent of health consequences
The limited information available on the pharmacology, 
dependence and abuse potential, and acute health 
effects of α-PVP have been discussed above (Section 
A2, Section B, Section D1, Section D2).
Based on animal model experiments (Section A2) as well 
as on self-reports and acute intoxications (Section D1.2), 
the acute behavioural effects of α-PVP, including effects 
on the ability to operate machinery and drive, might bear 
some similarities to those induced by other 
psychostimulants such as MDPV, cocaine, and 
methamphetamine.
Aggregated data related to cases of suspected driving 
under the influence of drugs (DUID) were reported to the 
EMCDDA. There are insufficient data available to discuss 
the circumstances of these cases.
D3.5. Long-term consequences of use
There is no data on the long term consequences of using 
α-PVP.
D3.6. Conditions under which the new 
psychoactive substance is obtained and used, 
including context-related effects and risks
It appears that α-PVP is sourced and used by individuals 
attempting to source the drug itself. Sources appear to 
include internet retailers, bricks-and-mortar shops, 
friends and other acquaintances, and street level drug 
dealers. In addition, the available data also supports the 
premise that some users are unaware that they have 
sourced and used α-PVP (Section C and Section D1.2).
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Based on the available data, it seems reasonable to 
consider that α-PVP is used in the same environments 
as other psychostimulants. This would be typically (but 
not restricted to) home environments, pubs/bars and 
discotheques/nightclubs, and outdoor music festivals 
(39). In addition, α-PVP is likely to be used in some of the 
other environments used by high risk drug users who 
inject opioids and stimulants (Section D1.2.3 and Giese 
et al., 2015; Sundström et al., 2015).
I Section E. Social risks
| E1. Individual social risks
There is no data on the effects of α-PVP on individual 
social risks.
| E2. Possible effects on direct social environment
There is no data on the possible effects of α-PVP on the 
direct social environment.
| E3. Possible effects on society as a whole
There is no specific data on the possible effects of α-PVP 
on society as a whole.
| E4. Economic costs
There is no data on the effects of α-PVP on economic 
costs.
Given the lack of data available on acute health 
emergencies and healthcare utilisation related to the use 
of α-PVP, it is not possible at this time to estimate 
whether this substance is associated with greater 
healthcare costs than other stimulant drugs.
(39) Data from the online survey conducted by the I-Trend project which 
was completed by 1074 Polish citizens aged 16+, found that out of 
36 respondents who reported α-PVP as the last new psychoactive 
substance they had used: 36.1 % (n=13) had last used α-PVP with 
friends either in their home or their friends home; 30.6 % (n=11) had 
last used α-PVP with friends outside/in the countryside; 16.7 % (n=6) 
had last used α-PVP alone at home; 8.3 % (n=3) had last used α-PVP 
with friends at a club, pub, or party; 5.6 % (n=2) had last used α-PVP at 
school or work; 2.8 % (n=1) had last used α-PVP in other 
circumstances.
|  E5. Possible effects related to the cultural context, for example marginalisation
There is no specific data on the possible effects of α-PVP 
related to the cultural context.
Data reported to the EMCDDA suggests the use of 
α-PVP by high risk drug users, including those who inject 
opioids and stimulants. These user groups are often 
marginalised.
|  E6. Possible appeal of the new psychoactive substance to specific population groups within the general population
There is no specific data on the possible appeal of α-PVP 
to specific population groups.
The available data suggests that α-PVP is used by 
recreational stimulant users and high risk drug users. In 
the latter case this includes people who inject opioids 
and stimulants. The extent of the possible appeal of 
α-PVP to these groups of users is unknown.
I  Section F. Involvement of organised crime
|  F1. Evidence that criminal groups are systematically involved in production, trafficking and distribution for financial gain
Poland reported the seizure of two illicit production sites 
synthesising α-PVP. The first production facility, where 
brephedrone was also manufactured, was seized in July 
2013 in Chorzow. Approximately 50 kg of α-PVP were 
produced in this site, which were destined both for the 
domestic market and for export. The second synthetic 
drug production facility, dismantled in October 2014 in 
Krakow, also produced brephedrone and NEB 
(N-ethylbuphedrone). The amount of α-PVP and 
brephedrone seized totalled 4.5 kg. According to the 
Polish authorities, both cases were linked to a local 
group of ‘football hooligans’. The synthesis was 
supervised by trained chemists, and the laboratories 
were operated by suppliers, producers and distributors 
of chemicals. The companies involved operated their 
own websites offering the sale and distribution of those 
substances across Poland.
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Hungary reported that α-PVP was detected in two tablet 
manufacturing sites, dismantled in 2013 and in 2014, 
respectively. The synthesis of α-PVP did not take place in 
these sites. The site seized in 2013 was a tableting unit 
where pentedrone tablets were produced; 24,908 
tablets containing pentedrone and 800 grams of α-PVP 
in powder form were seized. In 2014, the Hungarian 
police dismantled a tablet manufacturing site where 
pentedrone tablets were also produced. In the storage 
location linked to this site, 1.5 kg of α-PVP in powder 
form was seized. According to the Hungarian police, in 
both cases, the suspects intended to produce tablets 
using the α-PVP powder.
Information related to trafficking routes was provided by 
seven Member States (Bulgaria, France, Germany, 
Latvia, Luxembourg, Slovakia and Spain). In 10 of the 11 
cases where trafficking route information was provided, 
China was noted as the source country for α-PVP. In the 
remaining case, Poland was indicated as a country of 
origin. Germany and France would appear to be transit 
points in the EU, possibly due to the location of air 
freight hubs. The large quantities of α-PVP seized in or 
en-route to Spain suggest that it may be an important 
point in the distribution chain of α-PVP. Romania 
reported that the main source country for importation of 
α-PVP is China, mainly via mail parcels. The Czech 
Republic reported that α-PVP is imported using mail 
shipments and courier services.
Four Member States (Hungary, Latvia, Romania and 
Spain) provided information in relation to the 
involvement of organised crime in the manufacture or 
trafficking of α-PVP. Hungarian authorities reported that 
there are no ‘classical’ organised crime groups involved 
in the manufacture or trafficking of α-PVP. Latvian 
authorities reported that since 2014, a new trend has 
been observed in relation to the market in new 
psychoactive substances: a Latvian organised crime 
group was involved in the mixing and distribution of NPS 
in herbal form and in one such case, the herbal 
substance was mixed with α-PVP. Romania reported 
that criminal groups are not involved in the trafficking of 
α-PVP. Spain reported that they do not have any 
intelligence about α-PVP being linked to criminal groups.
|  F2. Impact on the production, trafficking and distribution of other substances, including existing psychoactive substances as well as new 
psychoactive substances
Based on the information available to the EMCDDA and 
Europol it does not appear that the production, 
trafficking and distribution of α-PVP impacts on other 
existing psychoactive substances or new psychoactive 
substances. α-PVP has been sold surreptitiously as 
drugs that are under international control, such as 
methamphetamine and MDPV, as well as ‘ecstasy’. The 
extent of this practice is unknown.
|  F3. Evidence of the same groups of people being involved in different types of crime
No information has been received by Europol of 
evidence of the same groups of people being involved in 
different types of crime in connection with α-PVP.
|  F4. Impact of violence from criminal groups on society as a whole or on social groups or local communities (public order and safety)
No information has been received by Europol on 
incidents of violence in connection with α-PVP.
|  F5. Evidence of money laundering practices, or impact of organised crime on other socioeconomic factors in society
No information has been received by Europol on 
incidents of money laundering or impact of organised 
crime on other socioeconomic factors in society in 
connection with α-PVP.
|  F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system)
There are no published data to be able to determine the 
impact of α-PVP in this area.
|  F7. Use of violence between or within criminal groups
There are no published data to be able to determine the 
impact of α-PVP in this area.
|  F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation
There are no published data to be able to determine the 
impact of α-PVP in this area.
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I Council Decision
COUNCIL IMPLEMENTING DECISION (EU) 2016/1070
of 27 June 2016
on subjecting 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, 
α-PVP) to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in 
particular Article 8(3) thereof,
Having regard to the proposal from the European Commission,
Having regard to the opinion of the European Parliament (2),
Whereas:
(1) A risk assessment report on the new psychoactive substance 1-phenyl-2-(pyrrolidin-1-
yl)pentan-1-one (α-pyrroli dinovalerophenone, α-PVP) was drawn up in accordance with 
Decision 2005/387/JHA by a special session of the extended Scientific Committee of the 
European Monitoring Centre for Drugs and Drug Addiction, and was subsequently 
submitted to the Commission and to the Council on 27 November 2015.
(2) α-PVP is a potent psychostimulant, structurally related to cathinone, pyrovalerone and 
methylendioxypyrovaleron (MDPV), which are controlled under the 1971 United Nations 
Convention on Psychotropic Substances. α-PVP has been detected in all 28 Member 
States, as well as Turkey and Norway, and the information from seizures and collected 
samples indicate that it is mainly present in powder and tablet form. The available 
information suggests that multi-kilogram quantities of α-PVP are imported into the Union 
drug market from China and then distributed across the Union. Two illicit production sites 
have been seized in a Member State, indicating that the capacity to manufacture α-PVP 
also exists within the Union.
(3) Eight Member States have reported a total of 115 deaths and 191 acute intoxications 
where α-PVP was detected. In most cases, the use of α-PVP was combined with other 
pharmacologically active substances, either intentionally or unintentionally. If α-PVP were 
to become more widely available and used, the implications for individual and public 
health could be significant.
(4) The available data suggests that α-PVP is used by stimulant users in recreational 
settings as well as by high-risk drug users, including those injecting stimulants and opioids, 
and that polydrug use may be common among them. There is limited data on prevalence of 
drug use, long-term consequences and on the social risks associated with the substance.
(1) OJ L 127, 20.5.2005, p. 32.
(2) Opinion of 8 June 2016 (not yet published in the Official Journal).
45/48
RISK ASSESSMENTS | α-PVP Annex 1
(5) There is no available information or any published study assessing in a comprehensive 
way the health risks associated with α-PVP, namely chronic and acute toxicity, but 
observations in animals suggest similar effects to those observed in other stimulants. 
Adverse symptoms observed in humans include tachycardia, hyperthermia, diaphoresis, 
agitation, convulsions or seizures, confusion and aggression. Data from non-clinical 
studies suggest that α-PVP may have an abuse liability and possibly a dependence 
potential in humans.
(6) α-PVP has no established or acknowledged human or veterinary medical use. Apart 
from its use in analytical reference materials and in scientific research investigating its 
chemistry, pharmacology and toxicology as a result of its emergence on the drug market, 
there is no indication that it is being used for other purposes.
 
(7) Despite the limited scientific evidence available on α-PVP, the evidence and 
information on the health risks that the substance poses, as documented in its detection 
in fatalities and acute intoxications, provides sufficient grounds for subjecting α-PVP to 
control measures across the Union.
(8) Given that 16 Member States control α-PVP under national legislation complying with 
the obligations of the 1971 United Nations Convention on Psychotropic Substances and 
that five Member States use other legislative measures to control it, subjecting this 
substance to control measures across the Union would help avoid the emergence of 
obstacles in cross-border law enforcement and judicial cooperation, and would help 
protect from the risks that its availability and use could pose.
(9) Decision 2005/387/JHA confers upon the Council implementing powers with a view to 
giving a quick and expertise-based response at Union level to the emergence of new 
psychoactive substances detected and reported by the Member States, by subjecting 
those substances to control measures across the Union. As the conditions and procedure 
for triggering the exercise of such implementing powers have been met, an implementing 
decision should be adopted in order to put α-PVP under control across the Union.
(10) Denmark is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision, which implements Decision 2005/387/JHA.
(11) Ireland is bound by Decision 2005/387/JHA and is therefore taking part in the 
adoption and application of this Decision, which implements Decision 2005/387/JHA.
(12) The United Kingdom is not bound by Decision 2005/387/JHA and is therefore not 
taking part in the adoption of this Decision, which implements Decision 2005/387/JHA, 
and is not bound by it or subject to its application,
 
HAS ADOPTED THIS DECISION:
Article 1
The new psychoactive substance 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one 
(α-pyrrolidinovalerophenone, α-PVP) shall be subjected to control measures across the 
Union.
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Article 2
By 3 July 2017, Member States shall take the necessary measures, in accordance with 
their national law, to subject the new psychoactive substance referred to in Article 1 to 
control measures and criminal penalties, as provided for under their legislation, complying 
with their obligations under the 1971 United Nations Convention on Psychotropic 
Substances.
Article 3
This Decision shall enter into force on the day following that of its publication in the Official 
Journal of the European Union.
This Decision shall apply in accordance with the Treaties.
Done at Luxembourg, 27 June 2016.
For the Council
The President
M.H.P. VAN DAM
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 Participants of the risk assessment meeting, 18 November 2015
Extended Scientific Committee
|  Dr Henri Bergeron, Centre National de la Recherche Scientifique (CNRS), Institut d’Études Politiques 
de Paris (IEP), Paris
|  Prof. Dr Gerhard Bühringer, Addiction Research Unit, Dep. of Clinical Psychology and Psychotherapy, 
Technische Universität Dresden, Institut für Therapieforschung (IFT), Munich, Chair of the Scientific 
Committee
|  Prof. Catherine Comiskey, Director, Centre for Practice and Healthcare Innovation, Trinity College 
Dublin
|  Dr Paul Dargan, Clinical Toxicology, St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation 
Trust, London
|  Prof. Gabriele Fischer, Medical University Vienna, Center of Public Health, Department of Psychiatry 
and Psychotherapy, Vienna
|  Prof. Dr Krzysztof Krajewski, Department of Criminology, Jagiellonian University, Kraków
|  Dr Fernando Rodriguez de Fonseca, Fundación IMABIS, Hospital Carlos Haya, Málaga
|  Prof. Dr Rainer Spanagel, Institute of Psychopharmacology, Central Institute of Mental Health, 
Mannheim
|  Prof. Félix Carvalho, Faculty of Pharmacy, University of Porto
|  Prof. Éva Keller, Semmelweis University, Department of Forensic and Insurance Medicine, Budapest
|  Prof. Ilkka Ojanperä, Department of Forensic Medicine, University of Helsinki
|  Dr Dariusz Zuba, Institute of Forensic Research, Krakow
|  Elsa Maia, DG Home, Anti-Drugs Policy Unit, European Commission, Brussels
|  Fabiano Reniero, Joint Research Centre, Institute for Health and Consumer Protection (IHCP), Ispra
|  Dr Leon Van Aerts, Section Pharmacology, Toxicology and Biotechnology (FTBB), College ter 
Beoordeling van Geneesmiddelen, Medicines Evaluation Board, Utrecht (on behalf of the European 
Medicines Agency)
|  Werner Verbruggen, Serious and Organised Crime Unit — Europol, The Hague
|  Paul Griffiths, Scientific Director, EMCDDA, Lisbon
|  Dr Roumen Sedefov, Head of unit, supply reduction and new drugs unit, EMCDDA, Lisbon
Invited external experts
|  Dr István Ujváry, Budapest University of Technology and Economics, Budapest
EMCDDA staff present
|  Ana Gallegos, Head of Sector, Action on new drugs, Supply reduction and new trends unit
|  Michael Evans-Brown, Scientific analyst, Action on new drugs, Supply reduction and new trends unit
|  Anabela Almeida, Project assistant, Action on new drugs, Supply reduction and new trends unit
|  Rachel Christie, Scientific analyst, Action on new drugs, Supply reduction and new drugs unit
|  Rita Jorge, Scientific analyst, Action on new drugs, Supply reduction and new drugs unit
|  Maria Moreira, Principal quality officer, Scientific Committee, Scientific division
|  Helene Jensvoll, Trainee, Action on new drugs, Supply reduction and new drugs unit
|  Agata Rybarska, Trainee, Scientific division
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